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Abstract 
Small interfering RNA (siRNA) shows great potential as a powerful tool in gene therapy, 
due to its ability to regulate gene expression in a highly selective manner. siRNA is a double-
stranded RNA consisting of 21–23 nucleotides and has the ability to trigger RNA interference 
(RNAi). RNA interference is the post-transcriptional gene silencing process where siRNA 
molecules bind to the complementary sequence in the target messenger RNA (mRNA), 
thereby inhibiting the expression of the target protein in cells. However, the clinical 
applications of siRNA are limited by the nature of naked siRNA molecules: Relatively large 
molecular weight, anionic nature and poor stability in physiological fluids of siRNA decrease 
its ability to permeate plasma membranes and result in inefficient cellular uptake. Thus, the 
development of efficient and safe delivery systems for siRNA has been an important research 
focus. Several strategies have been developed to aid in siRNA delivery, and peptide-based 
siRNA delivery reagents have been recognized as a promising approach for both in vitro and 
in vivo applications for more than a decade. 
The present study focuses on the design, modification and evaluation of novel co-
assembling, cell-penetrating peptides for siRNA delivery, including the following aspects: (1) 
design of new peptide sequences with incorporation of stearic acid, and modification of 
existing peptide sequences; (2) studying and improving serum stability without compromising 
gene-silencing efficacy; (3) investigation of the knockdown efficiency and toxicity of the 
resulting peptide/siRNA complexes in cultured cells and an animal model; (4) evaluation of 
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biocompatibility of the peptide/siRNA complexes in vitro; (5) studying of the internalization 
pathway, intracellular trafficking, and uptake mechanisms of the peptide/siRNA complexes. 
We previously reported a library of cell-penetrating, amino acid-pairing peptides that 
facilitate effective siRNA delivery to mammalian cells without causing cytotoxicity, but they 
are unstable in serum-containing media. Here, we investigated the possibility of conjugating 
the peptide with diethylene glycol to improve its serum stability without compromising its 
gene-regulation capability.  One of the most promising peptides in our library, C6M1 (with 
sequence: RLWRLLWRLWRRLWRLLR), was conjugated with diethylene glycol. The 
incorporated/co-assembled siRNA complexes increased in stability in serum from less than 24 
hours to up to 72 hours, with highly efficient cellular uptake and more than 90% cell viability 
profile. The gene-silencing ability of diethylene glycol conjugated-peptide/siRNA complexes 
was comparable to that of non-conjugated peptide/siRNA at both mRNA and protein levels. 
Despite the improved serum stability, the silencing efficiency of siRNA delivered by C6M1 
and the modified DM1 (degylated C6M1) ranged from 40% to 60%, and the less efficient 
knockdown ability might be due to the entrapment of siRNA in endosome/lysosome vesicles. 
Therefore, designing new sequences to enhance the endosomal escape of the complexes 
was required. A series of co-assembling, cell-penetrating peptides was designed, which 
comprised a variant of a nuclear localization sequence, i.e. PKPKRKV, 0-6 histidine residues 
and an optional stearic acid group. Among these candidates, the peptide STR-HK, with 
sequence of STR-HHHPKPKRKV, exhibited good characteristics as a safe and efficient 
siRNA delivery vector, facilitating efficient siRNA delivery to mammalian cells with only a 
15%-20% decrease in its cell viability. Moreover, the intratumoral injection of the STR-
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HK/siRNA complexes achieved high anti-tumor activity in mice, with an inhibition rate of 
62.8%. Our data revealed that introducing stearic acid into the peptide sequence improved its 
transfection ability, and the addition of histidine residues enhanced its endosome escape 
efficiency.  
However, the previously designed peptide STR-HK and the STR-HK/siRNA complexes 
induced strong cytotoxicity in vitro with increasing amounts of peptide, i.e., the cell viability 
of STR-HK/siRNA complexes dropped to 50% when the peptide concentration increased to 4 
µM. To decrease the toxicity of the delivery cargos, and further improve the gene-silencing 
efficiency, we designed a new series of cell-penetrating, co-assembling peptides, with the 
incorporation of stearic acid and a selected number of lysine, histidine and valine residues. 
The number of lysine, histidine and valine amino acids was carefully examined with respect to 
its binding affinity with siRNA molecules, and its gene-silencing efficacy induced by the 
corresponding peptide/siRNA complexes on a range of cell lines. Within the newly designed 
peptide family, the most pronounced gene silencing could be achieved with the peptide STR-
H3K3V6, sequence STR-HHHKKKVVVVVV. The cell viability was further improved 
compared to the peptide STR-HK. In addition, to address possible immune responses, the 
biocompatibility of the peptide STR-H3K3V6 was evaluated in terms of complement 
activation and cytokine activation, and no obvious responses were observed in vitro. 
Understanding the uptake mechanisms of our peptide-based siRNA delivery systems will 
facilitate the development of safe and efficient gene delivery vectors. Thus, the internalization 
process and intracellular trafficking of the STR-KV/siRNA complexes was explored. Heparin 
treatments revealed that the electrostatic interaction of our complexes with heparan sulphate 
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proteoglycans (HSPGs) at the cell surface was required to trigger the uptake process. Using 
physical and chemical endocytic inhibitors, it was found that the STR-KV/siRNA complexes 
mainly enter cells through an energy-independent mechanism, most likely involving direct 
translocation. The intracellular trafficking and internalization kinetics experiments further 
confirmed our complexes were uptaken through a non-endocytic pathway.  
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Chapter 1 
Introduction 
 
 
1.1 Overview 
The discovery of RNA interference (RNAi) by Fire et al. in 1998 has been widely 
regarded as the most promising breakthrough in gene therapy [1]. RNA interference is a 
highly efficient regulatory process present in most eukaryotic cells by which double-stranded 
RNA (dsRNA) cleaves complementary mRNA, resulting in post-transcriptional gene 
silencing. RNAi has been used in various areas, ranging from basic research to clinical 
applications, e.g. it can be used to determine the biological functions of proteins or pathways 
[2, 3]. Also, since short interfering RNA (siRNA) can turn off problematic genes, it shows 
tremendous promise in curing human diseases, e.g. cancer, HIV, viral infections, 
neurodegenerative disorders, and others [4-8]. The first clinical application with siRNA 
started in 2004 for age-related macular degeneration (AMD) [9], following with multiple 
clinical trials in different diseases conducted in past 10-15 years. Among these therapeutic 
applications, ALN-TTR02 (Alnylam Pharmaceuticals) was reported a success in Phase II 
clinical trial, and a Phase III study was initiated in mid 2014, which was the first siRNA-
based drug evaluated in Phase III clinical trials [10-13].  
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In basic experiments and therapeutic treatments, the long dsRNAs are commonly used to 
trigger the RNAi process as precursors of short interfering RNA[14]. After introduced into 
cytoplasm, the long dsRNA is firstly processed by the enzyme Dicer into siRNAs, and the 
siRNAs are then loaded onto RNA-induced silencing complexes (RISC) to initiate the RNAi 
processes [15, 16]. These post-processed siRNA are short duplexed RNA molecules, with a 
typical constitution of 19–23 nucleotides (nt) followed by two nucleotides at the 3’ end 
overhang on both the sense and anti-sense strands, approximately 7.5 nm long and 2 nm in 
diameter [4]. In addition to dsRNAs, synthesized siRNAs was also demonstrated to suppress 
silence targeting genes effectively [20]. After combining with siRNA, RISC then unwinds 
the RNA duplexes and releases the sense strand of siRNA, resulting in a functional siRNA-
RISC complex with guide strand of siRNA that directs a specific recognition of 
complementary mRNA [17-19]. The targeting mRNA is then cleaved near the middle of the 
region bound by the siRNA strand. After cleavage, the m7G cap or the poly-A tail that are 
essential to RNA stability is missing, induced a further degradation of mRNA fragments and 
prevention of protein expression. A schematic representation of RNA interference process is 
shown in Figure 1.1 [21]. 
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Figure 1.1 Schematic representations of RNA interference processes (Adapted from 
[10]). Step 1: dsRNA cleaves into fragments of 21-23 base pairs siRNA by the enzyme 
Dicer. Step 2: siRNAs are loaded into RISC and the sense strand is discarded and degraded, 
and the anti-sense strand remains within RISC as template. Step 3: the anti-sense strand 
assembles into an active RISC complex, which contains the siRNA bound to targeting 
mRNAs. Step 4: mRNA degradation is induced. 
 
Despite abundant promises, the development of RNAi therapies is limited by the 
unfavorable physicochemical properties of siRNAs, e.g., relatively large molecule weight, 
negatively charged surface, hydrophilicity, sensitivity to nuclease degradation, instability 
with short plasma half-lives (15 min to 1 hour) [16, 22]. It has been reported that chemical 
modifications in the sugars and the phosphate ester backbone of siRNA can improve its 
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nuclease resistance [9-11], and conjugation with hydrophobic groups with siRNAs can 
enhance its cell uptake with minor decrease of silencing efficiency. The development of 
efficient and safe delivery systems for siRNA has been applied as the main solution to 
overcome the obstacles [23]. The delivery systems can either self-assembled or covalently 
conjugated with siRNAs, designed to protect siRNAs from degradation while reducing the 
clearance rate of siRNAs and increasing the retention time. In addition, the delivery system 
should ensure effective biodistribution of siRNAs in the human body, facilitating cellular 
uptake and endosome release of siRNAs, while not inducing immune responses and have 
minimal toxicity. Different delivery strategies have been developed [24], including viral-
based strategy, as well as cationic polymers [25-28] and lipid- [29-31] or peptide-based [32-
35] vectors. Viral-based delivery strategies are considered the most efficient delivery systems 
[36], which have been applied in various in vivo studies [36, 37], e.g., Huntington’s disease, 
Alzheimer disease, Amyotrophic lateral sclerosis, and others. Although they exhibited high 
efficiency in vivo, the application of viral vectors is limited because of strong inflammatory 
responses caused by viruses [38]. Cationic lipids have been used to deliver siRNAs, and 
satisfactory results are achieved both in vitro and in vivo. However, studies demonstrate that 
cationic lipids may stimulate specific immune and anti-inflammatory responses [31], and 
may cause rapid elimination by reticuloendothelial system [39]. Although modifications have 
been made to address the toxicity issues, long term in vivo safety still remain in question and 
requires further investigation. Synthetic and natural polymers have been developed as siRNA 
carriers, which also suffer from toxicity and immunogenicity issues [33]. Thus, the clinical 
applications of polymer-based strategies have been hindered. Peptide-based carriers have 
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been developed as an alternative for safer in vitro and in vivo delivery. Consisted of 5–30 
amino acids, the peptides can cross cell membranes and facilitate cellular uptake of various 
molecules pharmaceuticals [40], such as siRNAs, DNAs, proteins, and others.  
Our group is focused on developing peptide-based siRNA delivery systems. A few 
peptide libraries have been designed and developed by our group members in past several 
years, in the aim of deliver siRNAs into cell with minimal toxicity. After high throughput 
screening, several peptides with high transfection efficiency were selected for further 
investigation. Physicochemical characterizations were studied first, including the interaction 
between peptides and siRNAs; the size and zeta potential; the morphology of the complexes, 
and others. The cellular uptake efficiency, as well as the cytotoxicity, knockdown efficiency 
on various cell lines, biocompatibility were then investigated with optimized concentrations 
and combinations of peptide/siRNA complexes. The uptake pathway and endosome release 
mechanism of complexes was also explored with selected candidates. To investigate the 
potential gene therapy in vivo, a human tumor xenograft in a nude mice model was applied to 
evaluate the in vivo efficacy and toxicity.  
Based on the results reported in this work, strategies could be developed to design 
efficient peptides to construct functional nanocarriers for in vitro siRNA delivery and cancer 
gene therapy. 
1.2 Objective 
The main objective of this study is to develop a safe and efficient peptide-based siRNA 
delivery system. To achieve this goal, modification and design of peptides are applied and 
   6 
studied in each chapter, including the interactions of peptide with siRNA, silencing 
efficiency and toxicity in vitro and in vivo, biocompatibility and serum stability of 
complexes, and also the cellular uptake pathways.  
The specific objectives are listed in the following: 
(1) Design of peptides to achieve high siRNA transfection efficiency and low 
cytotoxicity, including newly designed peptides and structurally modified peptides.  
(2) Characterize of peptide/siRNA complexes, including peptide and siRNA binding 
capacity and morphologies studies. 
(3) Investigate of silencing efficacy, toxicity, serum stability and biocompatibility of the 
complexes in vitro on selected cell lines. 
(4) Evaluate of the antitumor activity of complexes in vivo on a mouse xenograft tumor 
model. 
(5) Study the cellular internalization mechanism of the complexes. 
1.3 Thesis outline 
This thesis consists of seven chapters. The scope of each chapter is listed as follows: 
Chapter 1 gives a brief introduction of the thesis, including siRNA structure, RNA 
interference mechanisms, and the promising future of peptide-based siRNA delivery system. 
The research objectives and thesis organization are also given here.  
Chapter 2 presents a review of current and potential therapeutic applications of siRNAs, 
current gene delivery approaches including physical methods and viral and non-viral carrier-
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based delivery system. Cellular internalization pathways of siRNA delivery vectors are also 
reviewed in this chapter. 
In order to improve the serum stability of a previously reported peptide C6M1, a 
diethylene glycol moiety was added to C6M1. Physicochemical characterizations, serum 
stability, transfection efficiency of C6M1/siRNA and DM1/siRNA were conducted in 
Chapter 3. The diethylene glycol modification could improve the complexes stability without 
compromising the transfection efficiency.  
However, the knockdown efficiency of both complexes is very low. To enhance the 
transfection efficiency, a new peptide library was developed and evaluated in Chapter 4. The 
possibility of the introducing stearic acid into the peptide design was studied, with respect to 
complexes formulation, transfection efficiency, cytotoxicity, and in vivo xenograft model 
investigation. Peptide STR-HK showed great gene-silencing efficiency both in vitro and in 
vivo, yet the cell viability of complexes decreased with increasing amounts of peptide.  
To further improve the performance of peptide and complexes, a peptide library with a 
combination of stearic acid, lysine, and valine was developed and the structure-activity 
relationship of peptides is explored in Chapter 5. The optimal peptide with lowest 
cytotoxicity and highest transfection efficiency was determined on various cell lines.  
 In Chapter 6, the cellular uptake mechanism of the most promising candidates in chapter 
5 is investigated. The specificity of several chemical endocytosis inhibitors and 
internalization kinetics of the complexes were also studied. Chapter 7 summarizes the 
original contributions of this research and recommendations for future work. 
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The peptides used in each chapter are listed below: 
Table 1.1 Summary of peptides used in this thesis 
Chapter Peptide Sequences 
Chapter 3 C6M1 Acetyl-RLWRLLWRLWRRLWRLLR-NH2 
  DM1 Degylation-RLWRLLWRLWRRLWRLLR-NH2 
Chapter 4 H0K Acetyl-PKPKRKV-NH2 
 
HK Acetyl-HHHPKPKRKV-NH2 
 
STR-H0K Stearyl-PKPKRKV-NH2 
 
STR-HK (main) Stearyl-HHHPKPKRKV-NH2 
 STR-H6K Stearyl-HHHHHHPKPKRKV-NH2 
Chapter 5 STR-H0K3V6 Stearyl-KKKVVVVVV-NH2 
 
STR-H3K3V6 (main) Stearyl-HHHKKKVVVVVV-NH2 
 
STR-H6K3V6 Stearyl-HHHHHHKKKVVVVVV-NH2 
 
STR-H3K6V6 Stearyl-HHHKKKKKKVVVVVV-NH2 
 
STR-H3K9V6 Stearyl-HHHKKKKKKKKKVVVVVV-NH2 
 STR-H3K3V9 Stearyl-HHHKKKVVVVVVVVV-NH2 
Chapter 6 STR-KV Stearyl-HHHKKKVVVVVV-NH2 
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Chapter 2 
Literature Review 
 
 
2.1 RNAi Technology 
2.1.1 Applications of RNAi technology 
The applications of RNAi involve basic scientific research in gene therapy, e.g., 
functional genomics study [41, 42], the development of gene-specific drugs [7], and others. In 
basic biology research, short interfering RNA is a powerful tool to determine the biological 
functions of proteins or pathways [2, 3]. In pharmaceutical research, short interfering RNAs 
have been used as potential therapeutic agent to turn off problematic genes. Additionally, 
short interfering RNA therapies have been widely and effectively applied in the treatment of a 
variety of human diseases. Various studies have reported the success of silencing the disease 
genes by administration of siRNAs. SiRNAs show promising results as therapeutic agents for 
viral infections, cancer, HIV, and the applications of siRNAs have been extended into central 
nervous system therapeutics, as well as cardiovascular therapeutics, brain injuries, 
neurodegenerative disorders, and other fields [4-8]. Several types of diseases that are very 
common and are well studied in siRNAs field will be discussed in this chapter.  
Cancer 
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Cancer is one of the leading causes of death around world, especially in low- and mid- 
income countries. The number of deaths caused by cancer keeps growing, and is estimated to 
rise to 13.1 million in 2030 [15]. Current cancer treatment involves chemotherapy, radiation 
and surgery, and through significant progress has been made, there are still limitations. Studies 
demonstrate that various genes are involved in cancer development, and the mutations of these 
genes might cause uncontrollable cell proliferations and/or differentiations [43]. RNAi has 
advantages over regular cancer therapies, e.g., the specificity to inhibit target genes, and the 
relatively low toxicity to human beings. The application of RNAi technology provides a safe 
and efficient approach to reduce the expression of various oncogenes to a controllable level 
[4]. 
Oncogenesis. A number of genetic mutations are found in human cancer and can drive 
oncogenesis actively. The oncogene Bcl-2 for instance, is overexpressed in various human 
tumors [44]. Studies demonstrate siRNAs targeting the Bcl-2 gene can induce cell apoptosis 
both in vitro and in vivo [45]. Around 80 oncogenes are identified in breast cancer [4], 
including clusterin (Clu) [46], myelocytomatosis viral oncogene homolog (c-Myc), murine 
double minute clone-2 (MDM2) [47], FOXM1 [48], and others. Overexpression of Clu is 
reported to be associated with elevated tumor size. The silencing of Clu by siRNAs induced a 
decrease of cell proliferation and an increase of apoptosis rate in vitro, and a reduction of 
tumor increasing rate [46].  
Cell proliferation. Silencing the genes related to cell cycle might result in hindering cell 
division. Akt2 is related to the mitochondria subcellular localization and activation of p70S6K 
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pathway, and siRNA-targeting Akt2 can induce arrest of cell cycle in G0/G1 state [49]. 
Malignant transformation leads to tumor cell growth, adhesion, and migration. Studies show 
that N-acetyglucosaminyltransferase V (GnT-V) is overexpressed in various malignant tumors, 
and siRNA-targeting GnT-V has shown the potential of reducing cell proliferation rate and 
thus reducing metastasis and invasion possibilities [50].  
Angiogenesis. Angiogenesis is essential for neoplasia, and tumor metastasis, and is 
controlled by pro- and anti-angiogenic molecules in tumor [51]. Inhibition of angiogenesis 
results in limited tumor growth at a diameter of 2 mm [51, 52].  Vascular endothelial growth 
factor (VEGF) is up-regulated in various tumors, and RNAi technique applied to silence 
VEGF can successfully inhibit angiogenesis. Silencing VEGF intravenously and 
intratumorally in a pancreatic tumor xenograft model significantly down-regulated the 
expression of VEGF and thus reduced cancer cell proliferation and tumor growth [53]. An up 
to 97% decrease of tumor volumes was achieved by local delivery of chitosan/siRNA 
nanoplexes into rats with breast tumors [54]. 
Chemotherapy resistance. Drug resistance limits the effectiveness of chemotherapy.  The 
explanation of multidrug resistance (MDR) mechanisms involves the overexpression of P-
glycoprotein (P-gp) [55], ATP-binding cassette (ABC) transporters [56], multidrug resistance-
associated protein-1 (MRP1), and others. P-gp siRNA treatment induced almost complete 
restoration of intracellular accumulation of doxorubicin [57]. Silencing of the MRP1 gene 
leads to 85% to 90% reduction in MRP1 expression in doxorubicin-resistant MCR-7 cell line 
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[58]. Treatment with siRNA targeting on MRP1 resulted in the decrease of MRP protein in 
various human cancer cell lines, and improved epirubicin efficiency in vivo [59].  
Neurodegenerative diseases 
Neurodegenerative disorders are progressive diseases, accompanied by age-related loss of 
specific subsets of neural cells, and include Huntington’s disease (HD), Parkinson’s diseases 
(PD), Alzheimer’s disease (AD), and others. Currently, an effective therapy for most 
neurodegenerative diseases is unavailable [60], and the expensive treatments available may 
improve the symptoms or provide symptomatic relief, but may not change the progress of the 
diseases [61]. The estimated cost for the treatment of Alzheimer’s disease in the U.S. is 100 
billion annually in 1990s [62], and the number still keeps rising. A series of challenges for 
neurodegenerative disease therapies involve the effective crossing of blood-brain barrier 
(BBB) and blood-cerebrospinal fluid barrier (BCSFB) [63]. RNAi-based therapies have 
emerged as a promising treatment in neurodegenerative disease, which provides an approach 
to inhibit disease related genes. 
The first siRNA-based therapy for Huntington’s disease was reported in 2005, which 
demonstrated a success of inhibition of the target gene in striatum and cerebellum in vivo, and 
showed a significant improvement in pathology and behavior [64]. APP, BACE-1 and Tau are 
related to the treatment of Alzheimer’s diseases. Inhibition of BACE or APP expression 
resulted in the reduction of Aβ production in cultured neurons [65] or transgenic mouse 
overexpressing mutant APP [66]. Several successful investigations of RNAi-based therapy of 
neurodegenerative diseases on different animal models are summarized in Table 2.1 [67]. 
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Table 2.1 Summary of RNAi-based therapies of neurodegenerative diseases in vivo [67] 
Disease Animal 
model 
Agent Age Stage Outcome 
HD HD-N171-
82Q 
rAAV1-
shRNA 
4 weeks Presympt Partial prevention of inclusion 
formation, gait and rotarod 
abnormal phenotypes 
 R6/1 rAAV5-
shRNA 
6-8 
weeks 
Presympt Reduction in striatal inclusions, 
limited rescue of motor 
function and transcriptional 
dysregulation 
 R6/2 Liposom
e-siRNA 
Postnatal 
day 2 
Presympt Partial rescue of inclusion 
formation, weight loss, rotarod 
and open field. Mild effect on 
longevity 
 HD190QG rAAV5-
shRNA 
8-12 
weeks 
Sympt Reduced aggregates and 
increased DARPP-32 
expression; no 
behavioral/lifespan 
improvement 
SCA1 Ataxin1(Q
82) 
rAAV1-
shRNA 
7 weeks Presympt Prevention of inclusion 
formation and cell loss with 
partial improvement in rotarod 
performance 
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FALS SOD1(G9
3A) 
Lentiviru
s-shRNA 
7 days Presympt Delayed rotarod and gait 
abnormalities, weight loss, 
motor neuron death and animal 
demise 
 SOD1(G9
3A) 
Lentiviru
s-shRNA 
40 days Presympt Delayed disease onset, slowed 
motor dysfunction, reduced 
cell death and muscle atrophy 
 SOD1(G9
3A) 
Transgen
ic-
shRNA 
Breeding Presympt Delayed disease onset, death 
and partial prevention of motor 
neuron demise 
 SOD1(G9
3A) 
Transgen
ic-
shRNA 
Breeding Presympt Reversion to wild type 
behavioral and 
histopathological phenotype 
AD APP 
double 
transgenic 
Lentiviru
s-shRNA 
10 
months 
Sympt Reduced Aβ production, 
amyloid plaques and neuronal 
death; improved 
learning/memory 
 lv-APP HSV-
shRNA 
4 weeks Wild 
type 
Reduced APP expression and 
Aβ production by 
immunostaining 
PD lv-αsyn Lentiviru
s-shRNA 
Adult Wild 
type 
Silenced human synuclein 
transgene; no additional 
assessment 
1) Transgenic mice expressing shRNA were crossed with the mouse model of the disease. 2) 
Only in low copy number SOD1(G93A) transgenics. 3) The hippocampi of 4-week-old mice 
were co-injected with lentivirus expressing APP containing a disease mutation and herpes 
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simplex virus encoding a shRNA targeting the APP transgene. 4) Wild-type rats were 
coinjected with lentivirus expressing a human α-synuclein transgene and the therapeutic 
vector. 
 
Virus infection diseases  
Diseases caused by viral infection are another major causes of death worldwide. RNAi-
based therapies have been demonstrated effective to treat and prevent viral infections [68], 
including hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), 
human immunodeficiency virus (HIV), and others.  
HIV is a retrovirus that causes acquired immunodeficiency syndrome (AIDS). Despite 
decades of research, 33.4 million people are affected by AIDS and the number keeps 
increasing [8]. Current HIV treatment utilizes highly active anti-retroviral therapy (HAART) 
to improve the lives of patients, by decreasing the appearance of anti-HIV resistant strains 
[69]. However, HAART is limited by possible drug resistant variants, as well as the toxicities 
[70]. Studies show that siRNA targeting on various viral genes inhibits HIV replications 
effectively, including reverse transcriptase [71], Tat [72], Rev [73], Gag [74], CD4 [75], 
CCR5 [76], and others. The inhibition of CD4 through RNAi process [75] can successfully 
suppress viral entry, viral load, and others. Treatment with siRNA targeting CCR5 resulted in 
down-regulation target of the gene and an inhibition of HIV replications in various human cell 
lines and primary cell lines [77]. The first clinical trial of RNAi-based therapy for AIDS 
treatment was initiated in 2007 with a short hairpin siRNA (shRNA) vector rHIV7-shI-TAR-
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CCR5RZ (clinical government code NCT00569985), and the study is still ongoing but not 
recruiting participants. 
HSV-2 is essential for HIV-1 transmission [78], and more than 20% of U.S. population is 
affected by HSV-2 [79]. Treatment with siRNA targeting on UL-39 genes in HSV-1 can 
reduce the expression of target gene and thus inhibit HSV-1 replication in vitro [80]. In 
addition, siRNA-based microbicindes provides effective protection on mice against HSV-1 
infection [81]. 
HPV Infection results in patients who develop malignant tumors. Cervical cancer remains 
the most common cancer type in developing countries, and 0.5 million cases occur each year 
around the world [82]. More than 90% of cervical cancers are driven by viral protein E6 and 
E7 [83]. Studies show that treatment with siRNA targeting HPV 16/18 E6/E7 genes inhibits 
cervical cancer proliferation both in vitro and in vivo [84, 85]. Additionally, silencing E7 by 
siRNAs induced cancer cell apoptosis, and the expression of E7 can be reduced by 4-fold 
through RNAi processes [86]. 
2.1.2 RNAi in clinical trials 
Successes of in vivo experiments cultivated sufficient interest and confidence to initiate 
clinical applications. The first clinical trial with siRNA started in 2004 for treating age-related 
macular degeneration (AMD) [9]. Currently, multiple clinical trials are being conducted in 
areas including cancer treatments, diabetic retinopathy, hepatitis C, and others. Several of 
these clinical trials are listed in Table 2.2 [10, 87, 88].  
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Most siRNAs are administered by local delivery in clinical trials, especially the one with 
delivery strategy based on naked siRNAs. However, systemic administration is also required 
when intravitreal and/or intranasal routes are not appropriate for the diseases. 
Hypercholesterolemia, for instance, is treated through intravenous injection, in a Phase I trial 
was initiated by Tekmira with developed drug PRO-040201 targeting ApoB [89]. However, 
Tekmira terminated this clinical trial in early 2010, due to immune system activations. In 
contrast, ALN-PCS02 (developed by Alnylam Pharmaceuticlas) has been reported success on 
reduction of cholesterol in Phase I trial treating the same disease. In addition, Alnylam also 
successfully developed various siRNA-based candidates, including ALN-TTRsc, ALN-PCS02, 
ALN-VSP02, and others. To treat TTR-mediated amyloidosis, ALN-TTR02 was reported to 
significantly knockdown target protein by up to 93% in Phase II clinical trials, while this 
siRNA formulation was generally safe and well tolerated. Alnylam initiated Phase III trials of 
ALN-TTR02 with their partner Sanofi in mid 2014, and this is the first siRNA-based drug 
evaluated in a Phase III clinical trial [10-13]. 
Table 2.2 RNAi therapeutics clinical pipeline [10, 87, 88] 
Candidate Target gene Disease Phase Status Clinical Trial 
Gov. Identifier 
ALN-RSV01 Nucleocapsid  RSV infections II Completed  NCT00658086 
TKM-100201 VP24, VP35, 
Zaire Ebola 
l-polymerase  
Ebola virus 
infection 
I Terminated  NCT01518881 
TKM-080301 PLK1 Cancer I/II Recruiting  NCT01262235 
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ALN-VSP02 KIF11 and 
VEGF 
Solid tumours I Completed NCT01158079 
siRNA–
EphA2–DOPC 
EPHA2 Advanced cancers I Active  NCT01591356 
Atu027 PKN3 Advanced solid 
cancers 
I/II Recruiting  NCT01808638 
CALAA-01 RRM2 Solid tumours I Terminated  NCT00689065 
siG12D 
LODER 
KRAS Pancreatic 
cancers 
II Active  NCT01676259 
PRO-040201 APOB Hypercholeste-
rolemia 
I Terminated  NCT00927459 
ALN-PCS02 PCSK9 Hypercholeste-
rolemia 
I Completed NCT01437059 
ALN-TTR02 TTR TTR-mediated 
amyloidosis 
III Recruiting  NCT01960348 
ALN-TTRsc TTR TTR-mediated 
amyloidosis 
I Recruiting  NCT01814839 
   II Recruiting  NCT01981837 
ARC-520 Two 
conserved 
regions of 
HBV 
transcripts 
Hepatitis B I Recruiting  NCT01872065 
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   II Recruiting  NCT02065336 
ND-L02-s0201 SERPINH1 Liver fibrosis I Completed NCT01858935 
AGN211745 FLT1 Age-related 
macular 
degeneration 
II Terminated  NCT00363714 
PF-655 DDIT4 Age-related 
macular 
degeneration 
II Completed NCT00713518 
(PF-04523655) Choroidal 
neovascularizatio
n, diabetic 
retinopathy and 
diabetic macular 
edema 
II Completed NCT01445899 
Bevasiranib VEGFA Macular 
degeneration 
II Completed NCT00259753 
  Diabetic macular 
edema 
II Completed NCT00306904 
QPI-1007 CASP2 Optic atrophy and 
non-arteritic 
anterior ischemic 
optic neuropathy 
I Completed NCT01064505 
  Acute primary 
angle-closure 
II Active  NCT01965106 
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glaucoma 
SYL1001 TRPV1 Ocular pain and 
dry eye syndrome 
I/II Recruiting  NCT01776658 
SYL040012 ADRB2 Ocular 
hypertension and 
open angle 
glaucoma 
II Completed NCT01739244 
I5NP TP53 Kidney injury and 
acute renal failure 
I Completed NCT00554359 
  Delayed graft 
function and 
complications of 
kidney transplant 
I/II Active  NCT00802347 
RXI-109 CTGF Cicatrix and scar 
prevention 
I Active  NCT01780077 
  Hypertrophic scar Recruiting  NCT02030275 
  Keloid  Recruiting  NCT02079168 
TD101 KRT6A 
(N171K 
mutation) 
Pachyonychia congenita Completed NCT00716014 
  
Despite the exciting potential, various challenges limit the application of RNAi in 
therapeutics, including the instability of unmodified siRNA molecules in bloodstream, the off-
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target effects, the possibility of activating immune responses, and others. The development of 
a safe and efficient delivery strategy is now in urgent need.  
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2.2 Current delivery systems 
2.2.1 Challenges and barriers 
siRNA therapies have several advantages over traditional small molecule drugs. First, 
siRNAs can be rationally designed, while the traditional small molecule drug requires heavy 
screening processes prior to in vivo test, which is time-consuming and may be unsuccessful 
sometimes. In addition, siRNA therapies have relatively high specificity on their targeting 
sites, while traditional drugs are usually nonspecific accompanied by extensive side effects 
[90]. On the other hand, the applications of siRNA are limited by their poor stability, 
pharmacokinetics and off-target effects. Figure 2.1 lists the biological in vivo barriers of 
siRNAs [91].  
 
Figure 2.1 Schematic representations of in vivo siRNA systemic delivery key steps [91]. 
Steps 1-3 represent the in vivo delivery steps of siRNA systems. Steps 4-9 represent the 
processes of in vitro delivery steps of siRNA systems. 
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1) Biological instability 
SiRNAs are relatively stable in various conditions; for instance, their biological activity 
will not be changed with either short exposure to high temperature (less than 95ºC) or long 
incubation at low temperature (less than 1 year at 4ºC) [92], as long as no nuclease is present 
in the environment. However, during systemic delivery, siRNAs are exposed to nuclease 
degradation, and the reported half-life of unmodified siRNAs under physiological conditions 
ranges from 15 min to 1 hour [16, 22]. In addition, several studies demonstrate that siRNAs 
are preferentially taken up by the kidney, and will be eliminated within 1 hour due to their 
relatively low molecular weight (~13 kDa) [14, 15].   
2) Off-target effects 
Although it is believed to be highly specific and only affects the gene with a 
complementary sequence, RNAi also has the ability to induce non-specific off-target gene 
silencing [93]. Various mechanisms have been proposed, and it has been noticed that siRNAs 
can induce gene regulation of unintended transcripts through partial sequence 
complementarity in the seed region of siRNAs (positions 2-7) to the of the off target gene [94].  
3) Immune response 
Long dsRNA or high levels of siRNAs may stimulate the immune system and the 
production of cytokines both in vitro and in vivo, which involves the activation of interferon 
(IFN) and pro-inflammatory cytokines, e.g., IL-6, TNF-α, and COX-2 [95, 96]. Studies show 
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that the induction of the innate immune response is mediated by the binding of pattern 
recognition receptors known as Toll-like receptors (TLRs) with siRNA molecules, including 
TLR-3, TLR-7 and TLR-8 [97, 98]. SiRNAs induced immune response do so in a sequence-
dependent manner, for instance, TLR-7 and TLR-8 are more likely to be activated if siRNAs 
contain a 5’-GUCCUUCAA-3’ motif [99, 100]. 
4) Cellular uptake 
Due to the anionic nature and relatively large molecular weight, siRNAs cannot cross the 
cell membrane by themselves, and thus a delivery strategy is required to promote cellular 
internalization. Delivered by various delivery systems, siRNAs are mainly internalized 
through an endocytic pathway. After taking up the external nanoparticles, the early endosomes 
subsequently turn into late endosomes and then are relocated to lysosomes, which contain 
various nucleases to digest siRNAs with an acidic pH around 4.5. The siRNAs not escaping 
from endosome will be degraded eventually [101]. 
Some chemical modifications on siRNA molecules have been proposed to overcome 
these barriers without compromising the efficacy. Nuclease resistance, for instance, can be 
improved by introduction of a –O-CH2- linker at the 2’-fluoro, 2’-O-methyl, 2’-halogen, 2’-
amine, 2’-deoxy, and the bridging of 2’- and 4’-position of sugar of the ribose [15]. Moreover, 
2’-O-methyl on the sense strand can decrease the immune activation [102], and on the 
antisense strand can minimize the off-target effects [103, 104]. Besides, modifications on the 
backbone [105] and nucleobase [106] to protect siRNAs in serum and cytoplasm have also 
been investigated with success. 
   25 
In spite of these efforts, a safe and efficient delivery strategy is still required to facilitate 
the uptake of siRNAs to target cells to activate the RNAi processes. The efficient siRNA 
delivery strategies developed in the last 15 years involve different physical approaches, viral 
and non-viral delivery systems, and the direct uptake of naked siRNAs on certain cell lines 
[107]. Physical methods of mediating siRNA delivery, e.g., microinjection, electro-
permeabilization, have been investigated in siRNA application for more than 10 years [108, 
109]. Physical methods are highly efficient to deliver into small amounts of cells, and may 
avoid the stimulation of possible immune responses [109], but it will induce cell damage and 
lack the potential to be used for in vivo and therapeutic applications [110]. Viral delivery 
strategies, as well as the lipid-, polymer-, and peptide-based strategies, and targeting strategy 
will be discussed here.  
 
 
2.2.2 Viral based delivery systems 
Viral vector systems are considered as the most efficient strategy to deliver siRNAs into 
cells [36]. Various virus-based delivery strategies have been developed and optimized in vitro 
and in vivo, evaluating RNAi in the treatment of neurodegenerative diseases, retinal diseases, 
cardiac disease, viral infections, and cancer. Adeno-associated virus vectors (AAV) and 
lentivirus vectors (LV) are the most frequently used siRNA delivery vectors in a number of in 
vivo studies [36, 37], including mouse models of Huntington’s disease, Alzheimer disease, 
Amyotrophic lateral sclerosis, and others. 
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AAV serotype 1 vectors that mediate siRNA targeting of the human ataxin-1 gene driven 
by the pol III H1 promoter have been used to treat a mouse model of spinocerebellar ataxia 
type 1 (SCA-1) [107, 111]. Following injection into the cerebellum, the vector can resolve the 
disease-related inclusions found in SCA-1 mice and improve motor coordination. The first 
therapeutic application of viral vector-mediated siRNA was reported using LV vectors to 
target the prion protein (PrP) [112]. The LV/siRNA vector was injected into the hippocampus 
of mice with previously established prion disease. Reduction of up to 80% of hippocampal 
PrP mRNA expression was achieved with a single focal injection. Early behavioral deficits of 
prion disease were prevented, and the lifespan of the mice was increased by 23.5%. 
Unfortunately, non-specific cytotoxic effects were observed following treatment with 
LV/siRNA vectors. The comparisons of AAV and LV based delivery strategies are 
summarized in Table 2.3 [15]. 
Table 2.3 Comparison of AAV and LV based delivery systems [15] 
 Adenovirus-associated vectors (AAV) Lentivirus vectors (LV) 
Gene expression Transient or stable Transient or stable 
Integration into 
cell genome 
No Yes 
Immune 
stimulation 
Very low Low 
Advantages Non-inflammatory, non-pathogenic Persistent gene transfer in 
most tissues 
Disadvantages Small packaging size (4.5 kb) Integration might induce 
oncogenesis in some 
applications 
   27 
 
Although exhibiting high efficiency in vivo, the application of viral vectors is limited as a 
result of the strong inflammatory responses and caused by viruses [38]. Moreover, viruses can 
be rapidly eliminated by antibodies and immune systems of the host. Additionally, viruses 
may cause fatal diseases including allergy and virus infections. The clinical trials have been 
put on hold before the success development of a safe and suitable viral system [90, 113].  
 
 
2.2.3 Lipid based delivery systems 
Liposomes are the most commonly used methods for siRNA delivery, with an aqueous 
core enclosing hydrophilic drug in a phospholipid bilayer [114]. Lipoplexes are the complexes 
formed by liposomes and siRNAs, via hydrophobic and electrostatic interactions. The 
hydrophobic tails of lipids align with each other inside the lipoplexes, while the hydrophilic 
heads align outside to form a stable complex in aqueous solutions. Electrostatic interactions 
occur between the positive charges of the cationic lipids and the negatively charged phosphate 
backbone of siRNAs. The formulation of lipoplexes is highly effective, by general mixing of 
two components and incubating for different time periods. 
Cationic liposomes are the most commonly used non-viral delivery systems for nucleic 
acids, including plasmid DNAs, siRNAs, and oligonucleotides. Consisting of a positively 
charged cap, cationic lipids form complexes with siRNAs through electrostatic interactions, 
and can facilitate cellular uptake by interacting with negatively charged cell membranes [115]. 
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Although satisfactory results have been obtained both in vitro and in vivo, the severe toxicity 
and inflammatory effects limits the applications of siRNA delivery [116]. In addition, studies 
show that cationic lipids may activate the complement immune system causing rapid 
elimination by macrophages in reticuloendothelial system, and the high cytotoxicity to 
macrophage and other immune cells is a major concern (ED50 less than 50 nmol/l) [39]. Well-
developed cationic lipids based siRNA delivery strategy involves N-[1-(2,3-dioleoyloxy) 
propyl]-N,N,Ntrimethylammonium chloride (DOTMA), dioctadecylamido glycylspermine 
(DOGS), 3b[N-(N′,N′-dimethylaminoethane)-carbamoyl) cholesterol (DC-Chol), 
dimethyldioctadecyl-ammonium bromide (DDAB), dimyristyloxypropyl-3-
dimethylhydroxyethyl ammonium bromide (DMRIE), and 1-oleoyl-2-[6-[(7-nitro-2-1, 3-
benzoxadiazol-4-yl) amino]hexanoyl]-3-trimethylammonium propane (DOTAP) [117]. 
Neutral liposomes have been developed in the past decade, characterized of non-toxic and 
no immune activation. 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-oleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) have been proven to be successful for in vitro and in vivo siRNA delivery [118]. It 
has been reported that systemic intravenous injection of DOPC/siRNA nanoparticles can 
inhibit target protein expression 10-fold more efficient than cationic lipids/siRNA 
nanoparticles [119-121]. The third type of liposome based siRNA delivery systems is solid 
lipid-based strategy, e.g., stable nucleic acid lipid particles (SNALPs). The lipid bilayer of 
SNALPs consists by cationic and fusogenic lipids, which are coated with polyethylene glycol 
to avoid detection by macrophages and increase the circulation half-life of nanoparticles. 
Studies show the intravenous injection of SNALP/siRNA nanoparticles can inhibit 
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apolipoprotein B for 11 days [122], and the Phase I clinical trial of SNALP/siRNA targeting 
Plk1 was initiated in 2010 by Tekmira Pharmaceuticals (Burnaby, BC, Canada) (TKM080301) 
[123]. Alnlam Pharmaceuticals also developed SNALP based siRNA therapy, and initiated 
Phase I trial in 2009 (ALN-VSP02) [89]. 
Several modifications have been made to lipid-based carriers to increase their efficiency. 
Polyethylene glycol is added to carriers to prolong their circulation time in the blood and 
avoid being taken up by reticuloendothelial system, which is also known as “Stealth Liposome” 
[124]. Conjugating with a suitable antibody with high specificity and affinity for the target 
antigen, the efficiency of liposome uptake by the target tissue is increased [125]. Selected 
examples of the lipid-based siRNA therapeutic applications reported in vivo are shown in 
Table 2.4 [126]. Commercially available lipid-based transfection reagents include 
Lipofectamine (Invitrogen, life technology), RNAifect (Qiangen), Oligofectamine (Invitrogen, 
life technology), and others.  
Table 2.4 Examples of liposome/siRNA delivery systems applied in vivo [125] 
Liposomes siRNA target Animal model Results (gene silencing) 
DOPC liposomes EphA2 Orthotopic model 
of advanced 
ovarian cancer in 
female athymic 
nude mice 
86-91% reduction of tumor growth 
with combination therapy (siRNA-
liposomes and paclitaxel), 35-50% 
reduction of tumor growth with 
siRNA-liposomes alone 
SNALP HBV Female CD-1 Specific dose-dependent reduction 
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(modified) mice in HBV-mRNA 
SNALP ApoB Cynomolgus 
monkeys 
Dose dependent silencing of ApoB 
mRNA (about 90% for the 2.5 
mg/kg dose) 
SNALP ApoB 
(modified) 
Balb/C mice Potent silencing of ApoB mRNA 
(82%). Significant reduction in 
serum ApoB (74%), and 
cholesterol (52%) 
DOTAP 
liposomes 
TLR-4 Fenake C57BL/6 
mice 
Potent induction of both type I and 
II interferon response and 
activation of STAT1 
scL-HoKc HER-2 
(modified) 
Tumor xenograft 
in female 
athymic nude 
mice 
Silencing of target gene (virtually 
elimination of HER-2), 
downstream components and 
significan tumor growth inhibition 
CCLA-based 
cationic 
liposomes 
c-raf Human breast 
tumor xenograft 
model in SCID 
mice 
73% tumor growth inhibition 
DDAB/chlesterol 
liposomes 
Caveolin-1 Male CD1 mice Selective reduction of caveolin-1 
expression by about 90% within 
96h  
LIC-101 Bcl-2 
(human) 
Model of liver 
metastasis in 
male BALB/c 
75% tumor growth reduction 
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mice 
LNP01 Factor VII C57BL/6 mice Accumulation in liver (over 90%). 
Reversible, long-duration gene 
silencing without loss of activity 
following repeated administration 
 
 
2.2.4 Polymer and dendrimer based delivery systems 
Linear or branched cationic polymers with repeated units of monomers are another class 
of siRNA delivery system. Mono-dispersed dendrimers are highly branched cationic, the 
structures of which are usually three-dimensional spherical. The advantages of polymeric 
carriers in siRNA delivery are the precise nanoscopic size, controllable molecular weight, and 
the abundance of readily accessible terminal functional groups [127]. 
Several polymers have been designed and used in siRNA delivery: Poly(amidoamine) 
(PAMAM) dendrimers, poly(propylenimine) (PPI), poly(ethyleneimine) (PEI), poly-(L-
lysine) (PLL), poly(caprolactone) (PCL), poly(d,l-lactide) (PLA), and others. The 
modifications of these polymers and dendrimers have been investigated both in vitro and in 
vivo for siRNA therapy [16].  
PEI, a synthetic polymer, has been successfully used in siRNA delivery both in vitro [128] 
and in vivo [129]. In addition, studies show that PEIs can facilitate the endosome release of 
siRNAs to cytoplasm, due to it consisting of large number of protonable amino moieties [114]. 
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However, studies also show that PEIs may induce toxicity in vivo [130]. To overcome this, 
researchers investigated the relationship between molecular weight of PEIs and the biological 
activity, and demonstrate that PEIs with low molecular weight exhibit good biocompatibility 
with relatively low transfection efficiency [128]. Conjugated low molecular weight PEIs (1.8 
kDa) with PEG-stabilized liposomes, a micelle-like nanoparticles (MNP) have been developed 
with improved siRNA delivery efficiency and biocompatibilities [131]. 
PCL has been used in siRNA delivery for the past decade. A self-assembled MNP, 
consisting of monomethoxy poly(ethylene glycol) – block – poly(ε-caprolactone) – block – 
poly(2-aminoethyl ethylene phosphate) (PPEEA) (mPEG-b-PCL-b-PPEEA), has been 
developed and well characterized for siRNA delivery [132]. The biocompatible and 
biodegradable PPEEA can bind with siRNAs, while the PEG provides steric protection from 
nuclease degradation (Figure 2.2). It has been reported that siRNA delivered by these 
polymers induced 40% - 70% green fluorescence protein (GFP) suppression in cells, and 
successfully delivered to tumor in various animal models [133-135]. 
 
Figure 2.2 Structure mPEG-b-PCL-b-PPEEA MNP siRNA drug delivery systems [132].  
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To protect the complexes from degradation in serum, the complexes are coated or 
conjugated with PEG molecules. The triblock dendrimers PAMAM-PEG-PLL have been 
shown to be efficient nano-vectors for the delivery of siRNAs [136]. In this siRNA delivery 
system, the tertiary amine groups in the PAMAM dendrimer acts as a proton sponge and plays 
a vital role in endosomal escape and cytoplasmic delivery of siRNA. PLL is used to interact 
with siRNA and form stable structures, while PEG is used as a linker and also protects the 
system from nuclease attack.  
 
 
2.2.5 Cell-penetrating peptide based delivery systems 
Cell penetrating peptides (CPPs) are a class of peptides 5–30 amino acids long defined by 
the ability to cross cell membranes and the capacity to facilitate the cellular uptake of various 
molecular cargos [40]. A summary of current CPPs is listed in Table 2.5 [137]. CPPs based 
siRNA delivery system is relatively convenient compared with viruses or RNA chemical 
modification strategy. 
Table 2.5 Summary of cell penetrating peptides [136] 
CPPs Sequence Origin 
Cationic   
R6H4 RRRRRRHHHH Designed 
Penetratin RQIKIWFQNRRMKWKK  Antennapedia 
   34 
homeodomain 
(RXR)4 (R-Ahx8-R)4 Designed 
R9 RRRRRRRRR Designed 
NLS CGYGPKKKRKVGG SV40 NLS peptide 
 PKKKRKV Simian SV40 large tumor 
antigen 
KAFAK KAFAKLAARLYRKALARQLGV
AA 
Designed 
hCT(9–32) LGTYTQDFNKFHTFPQTAIGVGA
P 
A hormone secreted by the 
C cells of the thyroid 
TAT YGRKKRRQRRR HIV-TAT domain 
DPV3 RKKRRRESRKKRRRES Human heparin binding 
proteins and/or anti-DNA 
antibodies 
Amphipathic  
RGD GRGDSY Various circulating proteins 
Sweet arrow 
peptide (SAP) 
(VRLPPP)3 N-terminal domain of γ-zein 
hLF KCFQWQRNMRKVRGPPVSCIKR Antimicrobial peptides 
MPG GALFLGWLGAAGSTMGAPKKK
RKV 
HIV glycoprotein 41 protein 
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pVEC LLIILRRRIRKQAHAHSK Murine vascular 
endothelialcadherin protein 
ARF(1–22) MVRRFLVTLR IRRACGPPRVRV p14ARF protein 
BPrPp (1–28) MVKSKIGSWILVLFVAMWSDVG
LCKKRP 
The N-terminus of the 
unprocessed bovine prion 
protein 
Bac7 RRIRPRPPRLPRPRPRPLPFPRPG Bactenecin family of 
antimicrobial peptides 
MAP KLALKLALKALKAALKLA Chimeric 
DPRSFL DPRSFL Proteinase activated 
receptor 1 (PAR-1) 
VP22 NAATATRGRSAASRPTQRPRAP
ARSASRPRRPVQ 
Herpes simplex virus (HSV) 
vT5 DPKGDPKGVTVTVTVTVTGKGD
PKPD 
Viral proteins 
C105Y CSIPPEVKFNKPFVYLI The residues 359–374 of 1-
antitrypsin 
CADY GLWRALWRLLRSLWRLLWRA Designed 
Pep-1 KETWWETWWTEWSQPKKRKV A tryptophan-rich cluster 
p28 LSTAADMQGVVTDGMASGLDK
DYLKPDD 
Azurin 
Hydrophobic  
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PFV PFVYLI C105Y 
SG3 RLSGMNEVLSFRWL A randomized peptide 
library 
Pep-7 SDLWEMMMVSLACQY CHL8 
FGF PIEVCMYREP Cellular and viral proteins 
 
CPPs can be classified into several groups: cationic CPPs, hydrophobic CPPs, and 
amphipathic CPPs. Charged residues play an important role in the cellular uptake of cationic 
CPPs [138]. Studies on arginine-based peptides (from R3 to R12) have shown that the 
minimal sequence for cellular uptake is R8 and that increasing the number of arginine residues 
increases the level of uptake [139]. Studies also suggest that at least eight positive charges are 
needed for efficient uptake of several other cationic CPPs [140]. CPPs with positively charged 
residues can interact with cell surface glycosaminoglycans (GAGs) and enter the cell through 
endocytic pathways [138]. Although charged residues are very important in the uptake of 
cationic CPPs, other residues are also crucial. The uptake of Penetratin 
(RQIKIWFQNRRMKWKK), for instance, is abolished by the mutation of W14 to F [90, 141]. 
Nuclear localization sequences (NLSs) is another group of CPPs with lower than eight 
positively charged residues. Nuclear localization sequences are amino acid sequences, with 
the ability to translocate into the cell nucleus. Examples of NLSs [142] involve the mutation 
of simian virus 40 (SV40) with sequences of PKKKRKV, Oct-6 (GRKRKKRT), SDC3 
(FKKFRKF), and others. Since the number of positively charged residues in a NLS is usually 
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below eight, most of NLSs are not efficient siRNA delivery vectors [143]. They must be 
conjugated to hydrophobic segments to become amphipathic CPPs to be efficiently taken up 
by the cell.  
The first discovered CPP was the transactivating transcriptional activator (Tat) from 
human immunodeficiency virus 1 (HIV-1) by two independent groups in 1988 [144]. 
Sequence RKKRRQRRR, residues 49 to 57 from the Tat protein, is responsible for the cell 
penetrating properties of the Tat protein. Tat has been studied on multiple cell lines to deliver 
oligonucleotides [145], proteins and fluorophores. 
The first study of CPP mediated siRNA delivery was published in 2003 with peptide 
MPG [146]. MPG (GALFLGFLGAAGSTMGAWSQPKKKRKV), derived from NLS SV40, 
can induce an 80% reduction of luciferase activity in vitro after combined with siRNAs. Some 
modifications have been made to peptide MPG, and the derivatives as MPG-NLS and MPGα 
show enhanced transfection efficiency and increased binding affinity to siRNA molecules 
[147]. Several cell lines, such as HeLa [146], HEK-293 [148], and SW-620 [149], mediated 
by MPG/siRNA delivery systems shows good gene silencing results.  
Penetratin (RQIKIWFQNRRMKWKK) is another CPP that has been extensively 
examined for siRNA delivery [150]. Unlike most CPPs, penetratin enters cells in an energy-
independent matter, as penetratin can be internalized at both 4 and 37 °C. Studies on the 
penetratin sequence by Drin and co-workers demonstrate that the basic amino acids and the 
tryptophan at position 6 are crucial for efficient cellular uptake [151].  
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hCT (9-32) peptide, listed in Table 2.5, mediated siRNA delivery demonstrated 
knockdown results of  a G protein-coupled receptor, i.e., the human Neuropeptide Y Y1 
receptor [152]. siRNAs can be effectively delivered into HEK-293 cells with a comparable 
knockdown results induced by lipofection/siRNA complexes, while minimal cytotoxicity has 
been observed. The details of recent developed CPPs based siRNA delivery strategies can be 
found in a variety of reviews [40, 138, 153-156].  
 
 
2.2.6 Targeting strategy for siRNA delivery systems 
In order to reduce systemic toxicity while improving therapeutic efficiency, a conjugation 
with targeting ligands is the most commonly adopted methods. Passive targeting is developed 
based on enhanced permeability and retention (EPR) effect since 1986 [157, 158]. Passive 
accumulation has been applied in siRNA delivery system design, e.g., 80% tumor protein 
suppression has been observed after intravenous injection of liposome/siRNA into mice, 
followed by the accumulation of nanoparticles in tumor cells [120]. The EPR effect does not 
lead to exclusive tumor targeting, thus the efficacy of passive targeting is relatively low [158]. 
To enhance the accumulation of siRNAs in desired tumor sites, the active targeting 
strategy is incorporated in the design of siRNA delivery systems. The commonly adopted 
targeting ligands [159] involve antibodies, aptamers, small molecules, chemical modified 
polymers, short peptides, fatty acids, and others.  
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Antibody has been widely used to target cells of interests. Transferrin conjugated 
liposome can induce the nanoparticle accumulated in targeting sites 20 min after intravenous 
injection [160]. Human epidermal growth factor receptor-2 (Her2) antibody conjugated with 
siRNA delivery systems results an inhibited breast tumor cell proliferation [161]. However, 
the drawbacks of antibody targeting strategy include the relatively large size, and possibility 
of immunogenicity when long-term administered [162]. 
Another active targeting strategy is incorporating aptamers into siRNA delivery systems. 
Aptamers are characterized with high stability, unlimited shelf-life, no observed stimulation of 
immune responses [114], but the number of well-established aptamers for specific disease 
targeting is limited to a great degree.  
Tumor homing peptides remain a useful targeting strategy in developing siRNA delivery 
system. Arg-Gly-Asp (RGD) peptide for instance, listed in Table 2.5, has been effectively 
employed as targeting ligands. Chitosan conjugated with RGD exhibited an 80% in vivo 
mRNA suppression, and a 51% in vivo protein inhibition [164].  
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2.3 Cellular uptake pathway and endosome escape 
Typically, there are two main kinds of uptake pathways for nano-complexes: the 
endocytic pathway and the non-endocytic pathway. CPPs can be internalized through different 
pathways (Figure 2.3 [165]), including direct penetrating and enydocytic pathways. The 
internalization process can be influenced by various factors, including changes in membrane 
properties, particle shapes or charges, particle sizes [166]. After internalized through 
endocytic pathway, the carrier/siRNA nanoparticles tend to be trapped in endosome/lysosome 
vesicles, and degraded by multiple enzymes eventually. Thus, an efficient strategy needs to be 
applied to facilitate endosome escape, e.g. proton sponge effect, or the addition of fusogenic 
reagents. 
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Figure 2.3 Intracellular uptake pathways of CPP/siRNA nanoparticles [164].  
 
2.3.1 Uptake pathways and internalization mechanisms of CPP/siRNA complexes 
Endocytic membrane trafficking is a complicated process by which cells internalize 
solutes and fluids from the extracellular matrix. The endocytic pathways are divided into four 
groups: macropinocytosis, phagocytosis, clathrin-mediated endocytosis (CME), and caveolae-
mediated endocytosis (CvME).  
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Macropinocytosis is a signal dependent endocytosis [167]. This process presents in 
antigen-presenting cells, e.g., it may take place on macrophages cells when they actively 
responsed to colony stimulating factor-1 or epidermal growth factors. A number of CPPs are 
taken up by cells through macropinocytosis. TAT-PTD peptides, as well as TAT fusion 
proteins, are internalized through macropinocytosis [168]. Several inhibitors are reported to 
suppress macropinocytosis [166], e.g., rottlerin, amiloride, cytochalasin D, latrunculins, 
LY290042, sodium azide, and others.     
Phagocytosis mainly occurs in phagocytic cells, i.e., monocytes, neutrophils, 
macrophages and dendritic cells [169], while the other three types of endocytosis presents in 
almost all types of cell lines. Phagocytosis is mediated by membrane extensions, which are 
used to uptake large particles such as bacteria [170]. Phagocytosis is also mediated by various 
receptors, e.g., mannose receptor [171], scavenger receptor [172], fragment crystallizable 
receptor [173], and complement receptor [173]. The inhibitors used to identify phagocytosis 
pathway [166] involve amiloride, cytochalasin D, latrunculins, wortmannin, LY290042, 
sodium azide, and others. 
Clathrin-mediated endocytosis is a type of pathway that requires GTPase dynamine and 
receptors, while clathrin helps to form a coated cavity in the cell membrane with size ranges 
from 100 nm to 150 nm [174]. Lipoproteins with relatively low density are usually 
internalized through CME pathway [174]. Different from the other three types of endocytosis, 
nano-particles internalized via CME are directly integrated into late endosomes, and 
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eventually transported into lysosomes [175]. The inhibitors related to CME pathway [166] 
include chlorpromazine, monodansylcadaverine, phenylarsine oxide, sodium azide, and others.  
Caveolae-mediated endocytosis is a receptor-specific pathway with size ranges from 50 
nm to 100 nm, which requires the presenting of cholesterol and dynamin [176]. CvME is 
mediated by various receptors, e.g., insulin receptors [177] and epidermal growth factors [178], 
and others. Studies show TAT-rhodamine [179], as well as TAT-GFP [180], are internalized 
through CvME pathway. In addition, amphipathic CPPs with proline riched sequences [181], 
as well as certain viruses (e.g., SV40), bacteria, and bacteria toxins [182], are also internalized 
via CvME. Inhibitors such as filipin, nystatin, cholesterol oxidase, statins, genestein, MBCD, 
sodium azide, and others are normally used to characterize CvME pathway [166].  
Direct penetration is a receptor- and energy-independent uptake pathway that is driven by 
plasma membrane potentials, which allows nanoparticles to cross the cell membrane directly 
and avoid entrapment in endosome/lysosome vesicles. Thus, siRNAs internalized through 
direct penetration may achieve a better biological activity. Various CPPs-based siRNA 
delivery systems are reported to enter the cells through direct penetration, including CADY 
[183], HR-9 [184], and TAT in some cases [185].  
The uptake pathway of CPP-based siRNA delivery system are subject by various factors, 
including particle sizes, surface charges, particle shapes, cell types, and others. Studies 
demonstrated that the internalization of certain nanoparticles might involve several pathways 
at the same time, which may be due to heterogeneity of the complexes [186]. Another factor 
that may influence cellular uptake pathways is the concentrations of nano-vectors. It has been 
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noted that CPPs at low concentrations are commonly internalized through endocytic pathways, 
while CPPs at high concentrations tend to be taken up via direct penetrations [187, 188].  
As discussed previously, various biological tools are explored to determine the specific 
cellular uptake pathway for certain nano-vectors. Endocytosis pathway inhibitors that 
specifically block one or several pathways can be used to determine the pathways involved in 
the internalization processes. Inhibitors for each pathway are discussed previously. It is worth 
noticing that sodium azide, an inhibitor of mitochondrial oxidative phosphorylation, is 
involved in all kinds of endocytosis pathways [189-191]. Also, the impact of temperature is 
another method commonly adopted to determine whether the internalization of certain nano-
vectors is through energy-independent pathways.  
Other useful tools to investigate uptake pathways include the molecular probes, markers, 
and dyes. Transferrin is a classic molecular probe specifically internalized through the CME 
pathway. Caveolin-1 is the popular marker for CvME. Dextran is an essential probe for 
macropinocytosis. LysoTrackers is a widely used dye for endosome/lysosome vesicles, and it 
is commonly used in combination with confocal microscopy to study the intracellular 
trafficking of nanoparticles.  
 
2.3.2 Endosome escape mechanisms and strategies 
After endocytosis, nanoparticles might be trapped in endosome/lysosome vesicles. Figure 
2.4 illustrates the overall endosome escape processes for siRNA delivery systems [192].  
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A number of mechanisms have been proposed. One of these mechanisms is the formation 
of pores on cellular/endosomal membranes. Complexes with high binding affinity to the lipid 
bilayers can insert into membranes and then create a pore on the membranes. Cationic 
amphiphilic peptide is one of the best-known examples of a complex capable of pore 
formation on cellular/endosomal membranes.  
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Figure 2.4 Endosome escape in lipoplex mediated siRNA delivery [192]. A. Lipoplex 
containing siRNA (shown as orange lipid bilayer and red siRNA) with PEG and targeting 
ligand on the tip (shown as blue circle) are taken up by target cell via receptor mediated 
endocytosis. B. The cationic lipid of the lipoplex forms ion pairs with the anionic endosomal 
lipid (PEG molecules may leave the lipoplex spontaneously or under appropriate design) and 
can further form the inverted hexagonal phase (HII). This leads to the fusion of the lipoplex 
with endosomal membrane and release the siRNA into cytoplasm. C. Lipoplex containing 
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molecules having buffer capacity in endosomal pH range can trigger proton sponge effect 
that causes the influx of Cl− and swelling of the endosome. D. Free highly positive charged 
molecules (shown with orange colored cationic lipid and purple colored PEI or oligo-
arginine) can interact with anionic endosomal membrane and destabilize it by 
excludingwater. E. Intact lipoplex mayescape from the ruptured endosome and de-assemble 
in the cytoplasm and release siRNA if the particle is not too large for the “holes” of the 
ruptured endosome. F. Lipoplex may also de-assemble inside the endosome and directly 
release siRNA out of the ruptured endosome.  
 
 
Another proposed mechanism for endosomal escape is through proton sponge effect. The 
proton sponge effect is induced by the influx of ions into endosome, leading to an increase of 
osmolality and the following rupture of endosomal membrane, with entrapped complexes 
released eventually [192]. Nanoparticles containing histidine residues may apply to this 
mechanism [40, 193]. The imidazole group of histidine with a pKa of 6 is able to absorb 
protons in the acidic environment of endosomes. The incorporation of polyethyleneimine is 
another way to introduce protonable groups into siRNA delivery systems [194]. 
Photochemical internalization is also proposed as an endosome escape strategy. When 
photosensitive complexes exposed to light, they will trigger the generation of highly reactive 
singlet oxygen. Singlet oxygen disrupts the endosomal membrane causing the release of the 
particles into the cytoplasm [195]. A number of photosensitizers can be used to formulate 
delivery systems with lipids [196], polymers [197], and CPPs [198]. 
Endosomolytic reagents that are able to disrupt endosomal membranes can be used in 
combination with CPPs to enhance endosome release of complexes. Chloroquine for instance, 
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can disrupt endosomal membranes by inhibiting endosome acidification processes [137]. 
However, chloroquine is not suitable for in vivo applications. Several other reagents with 
similar membrane disruption capabilities are also used for siRNA delivery purposes [138], 
including ammonium chloride, methylamine, and others. As alternatives, a number of 
endosomolytic peptides, also known as fusogenic peptides, can be used to improve endosome 
escape. These peptides undergo conformational changes in response to acidification of the 
endosome. HA2 peptide, derived from influenza virus, is the most commonly used fusogenic 
peptide. Studies demonstrate that fusion of HA2 with penetratin can improve transfection 
efficiency compared to penetration alone [139]. Similarly, the biological activity of TAT can 
be enhanced by fusion with HA2 [140].  
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Chapter 3 
DEGylation enhanced the stability of peptides-siRNA complexes 
in serum 
 
 
 
3.1 Introduction 
Since the discovery of RNA interference in mammals [1], short interfering RNA (siRNA), 
also known as small interfering RNA, has shown great potential as a powerful tool in gene 
therapy [23]. siRNA is a double-stranded RNA consisting of 21 – 23 nucleotides and has the 
ability to bind to the complementary sequence in a target mRNA, thereby inhibiting the 
expression of the target protein in cells [1]. However, the application of siRNA is limited by 
the nature of naked siRNA molecules, such as the relatively large molecular weight, anionic 
nature, poor stability in physiological fluids, which decreases their ability to permeate plasma 
membranes and results in an inefficient cellular uptake [199]. Thus, the development of 
efficient and safe delivery systems for siRNA has been an important research pursuit [23].  
Several strategies have been developed to aid in siRNA delivery [200], including the use 
of cationic polymers [201-203], and lipid- [204-206] and peptide-based [90, 144, 207, 208] 
non-viral vectors. These vectors form complexes with negatively charged siRNA molecules, 
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thus facilitating their cellular uptake and protecting them from nuclease interactions [209, 
210].  
Recently, we reported the development of a library of peptide-based siRNA carriers that 
cause gene knockdown without inducing cellular toxicity [211]. However, a major limitation 
of these carriers is that the transfection efficacy is reduced by the presence of serum, resulting 
in reduced gene knockdown efficiency. There are several ways that siRNA delivery systems 
might be affected by the presence of serum. For example, the positively charged complexes 
formed by siRNA and carriers might interact with negatively charged serum proteins, e.g., 
albumin, which would change the surface charge on complexes and cause the complexes to 
aggregate [212, 213]. Moreover, interactions with serum components could cause the 
disassembly of the siRNA delivery system and expose siRNA molecules to nucleases [214]. 
Currently, conjugating delivery complexes with polyethylene glycol (PEG) is a commonly 
used technique for improving the serum stability of gene delivery systems [215-218]. 
Conjugating with PEG molecules sterically shields the complexes [219] and reduces the 
interactions between the complexes and serum components [220]. PEGylation is also thought 
to decrease the uptake of the carrier/siRNA complexes by the reticuloendothelial system, 
which would prolong their circulation time in the blood [216]. However, after being 
conjugated with PEG, the gene delivery systems frequently exhibit reduced target specificity 
in vivo due to steric hindrance between the PEGylated systems and the target area [221]. It has 
also been suggested that transfection efficiency might by reduced by PEGylation because 
adding PEG molecules has the potential to reduce electrostatic interaction between positively 
charged delivery systems and negatively charged cell membranes [222]. 
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Herein, we report the results of conjugating one of the most promising library peptides 
[211], C6M1 (results has been published in [223-225]), with a short ethylene glycol, 
diethylene glycol (DEG), instead of PEG, considering the small size of the peptide and that 
anything to conjugate it should be comparable in size. The aim of this study is to determine 
whether DEGylation can improve the complex’s serum stability without compromising its 
transfection efficiency. For this purpose, we compared peptide/siRNA complexes that were 
either modified with DEGylation or without. Serum stability was examined by gel 
electrophoresis assay. Cellular uptake efficiency and cytotoxicity of complexes were 
investigated in Chinese hamster ovary (CHO-K1) cells. The efficiency of gene silencing in 
CHO-K1 cells was evaluated using RT-PCR and GAPDH assays, and it was evaluated in 
mouse endothelial cells that encoded the enhanced green fluorescence protein (GFP cells) 
using the eGFP silencing assay.  
This Chapter is based on the work published in Journal of Nanoscience and 
Nanotechnology, with authorship as: Ran Pan, Wen Xu, Mousa Jafari, Baoling Chen, Tatiana 
Sheinin, Pu Chen. 
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3.2 Materials and Methods 
3.2.1 Preparation of complexes 
Synthesized by CanPeptide Inc (Quebec, Canada), C6M1 and DEGylated C6M1 (termed 
DM1) peptides were dissolved in RNase free water (Thermo scientific, Ottawa, Canada) at a 
concentration of 1 mM, followed by sonication for 10 min, and were stored at -20°C. The 
peptide/siRNA (both C6M1/siRNA and DM1/siRNA) complexes were prepared in RNase free 
water for characterization experiments, and were prepared in Opti-MEM (Invitrogen, 
Carlsbad, CA, USA) for transfection experiments. The peptide/siRNA complexes were 
prepared at different molar ratio ranged from 1/1 to 80/1 depending on the designed 
experiment, by slowly mixing the peptide solution into siRNA solution. The complexes were 
incubated at room temperature for 30 min before conducting experiments.  
siRNA targeting at the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was 
purchased from Ambion (SilencerTM GAPDH siRNA: human, mouse, rat). The eGFP siRNA 
was purchased from Dharmacon, U.S.A, with an extinction coefficient of 362408 L/mol cm. 
The sense sequence of eGFP siRNA was 5’-GACGUAAACGGCCACAAGUUC-3’, and the 
antisense sequence was 5’-ACUUGUGGCCGUUUACGUCGC-3’. The negative control 
siRNA with scrambled sequence used in the experiment was also purchased from Ambion. 
3.2.2 Gel electrophoresis assay 
The interaction of peptide/siRNA complexes was investigated using agarose gel 
electrophoresis assay. Peptides (C6M1 and DM1) were mixed with siRNA targeting eGFP 
(peptide/sieGFP complexes) and were prepared as described above, with a final amount of 200 
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ng siRNA per well. The complexes were incubated at room temperature for 30 min before 
being loaded onto a 1.2% w/v agarose gel labeled with ethidium bromide in TBE buffer and 
run at 50 V for 60 min.  
3.2.3 Cell culture and peptide mediated siRNA transfection 
Transfection experiments were conducted using CHO-K1 cells and C166-GFP cells.  
All cell lines were obtained from ATCC (Rockville, MD, USA). 
The CHO-K1 cells (ATCC: CCL-61) were maintained in F-12K medium (Thermo 
scientific, Ottawa, Canada) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, 
Oakville, Ontario, Canada) at 37°C in 5% CO2. Before transfection, CHO-K1 cells were 
seeded in 24-well plates with a confluence of 35,000 cells/well and in 96-well plates with a 
confluence of 6,000 cells/well. After incubating at 37°C for 24 hours, cells were rinsed with 
phosphate buffered saline (PBS), which was then replaced with Opti-MEM. The 
peptide/siGAPDH complexes were prepared as described above, diluted in Opti-MEM to a 
final concentration of 50 nM siRNA and then added to each well. After the cells were 
incubated at 37°C for 4 hours, medium containing FBS was added to obtain a final 
concentration of 10% FBS. 
The C166-GFP cells (ATCC: CRL-2583) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Thermo scientific, Ottawa, Canada) containing 10% FBS at 37°C in 5% 
CO2. The GFP cells were seeded in 24-well plates at 35,000 cells/well and incubated for 24 
hours before transfection. The cells were rinsed with PBS, and Opti-MEM was then added. 
The peptide/sieGFP complexes were prepared as described above and were added to each well 
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at a final concentration of 50 nM siRNA. To maintain cell growth, FBS was added after 4 
hours of incubation to achieve a final concentration of 10%. 
3.2.4 Serum stability of complexes 
The protection afforded by peptide/siRNA complexes against serum components was 
evaluated by agarose gel electrophoresis assay. The peptide/sieGFP complexes were prepared 
as described above, with a final amount of 200 ng sieGFP per well, and incubated for 30 min 
before the addition of FBS. Active FBS was added to each well at a final concentration of 50% 
v/v, and inactivated FBS was used as control. Aliquots were taken at different time points, and 
1 µl of 0.5 M EDTA was immediately added to each sample to stop serum interactions. 
Heparin was then added to samples at a final concentration of 1.5% v/v, and the samples were 
incubated for 30 min before being loaded onto a 1.2% w/v agarose gel labeled with ethidium 
bromide (EtBr) at and run at 50 V for 60 min. The gel products were then visualized using a 
UV transilluminator.  
3.2.5 Cytotoxicity of complexes 
The cytotoxicity of peptide/siGAPDH complexes was evaluated using 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. CHO-K1 cells were 
seeded in 96-well plates at 6,000 cells/well and transfected with peptide/siGAPDH complexes, 
as described above. After 48 hours, cells were rinsed with PBS, and 100 µL of MTT solution 
(5 mg/mL in PBS) was added to each well. After 2 hours of incubation at 37°C, 100 µL of 
solubilization solution, composed of 10% Triton X-100 (Sigma) plus 1% HCl (Sigma) in 
anhydrous isopropanol (Invitrogen), was added to each well to dissolve the formazan crystals. 
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The optical densities were then measured at 570 nm with a microplate reader (FLUOstar 
Optima, BMG Labtech, Ortenberg, Germany). Cell viability was calculated as the optical 
density of each sample divided by the optical density of untreated controls. All measurements 
were performed in triplicate. 
3.2.6 Uptake efficiency of complexes 
The cellular uptake efficiency of complexes was studied by flow cytometry (type BD 
Biosciences, BD FACS Vantage SE Cell Sorter, USA). CHO-K1 cells were seeded in 24-well 
plates and transfected with peptide/Cy-3-labeled siRNA complexes 24 hours later, as 
described above. After 4 hours of incubation at 37°C, cells were rinsed with PBS and 
incubated in 15 U/ml heparin medium for 20 min. This step was repeated 3 times. Cells were 
then washed twice with PBS, detached from the plate with 0.25% trypsin/EDTA, and then 
collected in the suspension of 4% PFA in PBS. The collected samples were analyzed by 
fluorescence acquired cell sorting (FACS), and the data were analyzed by Flowjo software. 
All measurements were performed in triplicate. 
3.2.7 Fluorescence microscopy 
The cellular uptake efficiency of complexes was studied by fluorescence microscopy. 
CHO-K1 cells were seeded in 24-well plates at 60,000 cells/well, and transfected with 
peptide/Cy-3-labeled GAPDH siRNA complexes 24 hours later, as described above. After 4 
hours of incubation at 37°C, cells were rinsed with PBS and incubated in 15 U/ml heparin 
medium for 20 min. This step was repeated 3 times. Cells were then washed twice with PBS, 
and fixed with 500 µl/well of 4% PFA in PBS at 37°C. After 30 min, the fixation PBS was 
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aspirated, and the cells were washed twice with PBS before they were covered with 
Fluoroshield with DAPI mounting medium (Sigma-Aldrich, Oakville, Ontario, Canada). The 
samples were visualized on EVOS FL cell imaging system (Life Technology, Carlsbad, USA), 
with a 40x objective lens. A Sony ICX445 CCD of 1.3 megapixels was installed on the 
microscope. 
3.2.8 GAPDH silencing assay at mRNA level 
The efficiency of GAPDH siRNA interference was evaluated using real time RT-PCR that 
shows the gene knockdown on mRNA level. GAPDH primers used in this experiments are 
shown below: 5’-TGT GTC CGT CGT GGA TCT GA-3’ (F), 5’-TTF CTG TTG AAG TCG 
CAG GAG-3’ (R). CHO-K1 cells were seeded in 24-well plates and transfected with 
peptide/siGAPDH complexes 24 hours later, as described above. After 48 hours, total RNA 
was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and the RNA 
concentration was measured using Nanodrop (Nanodrop spectrophotometer ND-1000, 
Thermo scientific, Ottawa, Canada). RNA was then reverse transcribed into cDNA using Bio-
Rad iScript cDNA synthesis kit (Bio-Rad Laboratories, Ontario, Canada). RT-PCR was 
performed using the Mx3005P™ Real Time PCR System (Agilent Technologies, Wilmington, 
DE, USA) with Brilliant II Fast SYBR Green QPCR Master Mix (Agilent Technologies), 
according to the manufacturer’s instructions. All measurements were performed in triplicate. 
The data was normalized to cyclophilin genes, with primer sequences as: 5’-
GGTGATCTTTGGTCTCTTCGG-3’ (F), and 5’-TAGATGCTCTTTCCTCCTGTG-3’ (R). 
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Cyclophilin are a family of proteins that catalyzes the isomerization of peptide bonds from 
trans form to cis form at proline residues and facilitates protein folding. 
3.2.9 GAPDH silencing assay at protein level 
The amount of GAPDH protein expression was measured using the GAPDH KDalert 
assay kit (Ambion, Austin, TX, USA). CHO-K1 cells were seeded in 96-well plates and 
transfected with peptide/siGAPDH complexes 24 hours later, as described above. After 48 
hours, cells were rinsed with PBS and lysed with KDalert lysis buffer; they were then 
processed according to the manufacturer’s instructions. Fluorescence was measured at room 
temperature with microplate reader (FLUOstar Optima, BMG Labtech, Ortenberg, Germany). 
All measurements were performed in 5 wells in parallel. 
3.2.10 eGFP silencing assay 
C166 GFP cells were seeded in 24-well plates and transfected with peptide/sieGFP 
complexes 24 hours later, as described above. After 48 hours of incubation, the cells were 
rinsed with PBS and collected in 4% PFA solutions. The samples were evaluated by FACS, 
and the results were analyzed by Flowjo software.  
3.2.11 Serum effect on knockdown experiments  
24 hours before the transfection experiment, CHO-K1 cells were seeded at 6,000 cells/well 
into 96-well plates in F-12K medium with 10% FBS. The cells were rinsed with PBS and 
replaced with fresh F-12K medium containing 10% FBS. The peptide/siGAPDH complexes 
were prepared as described above and were added to CHO-K1 cells at a final concentration of 
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50 nM siRNA for 4 hours, followed by the addition of fresh F-12K medium with 10% FBS in 
the same amount as the previously described transfection experiment. After 48 hours of 
incubation, the cells were processed using the KDalert GAPDH assay kit, according to the 
manufacturer’s instructions. 
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3.3 Results and Discussions 
In developing an efficient siRNA delivery system, several important factors need to be 
considered. First, the delivery system must protect siRNA from being affected by its 
surroundings, which can include degradation caused by RNAse and aggregation caused by 
proteins. Second, the delivery system should deliver siRNA into cells and facilitate the RNAi 
process. Moreover, the delivery system should not cause cytotoxicity, either in vitro or in vivo.  
Considering these factors, i.e. peptide siRNA co-assembly, siRNA loading and protection 
capability, peptide/siRNA complexes transfection efficiency, peptide C6M1 was designed 
previously by our group. The sequence was listed in Table 3.1.  To determine whether 
DEGylation can improve the complex’s serum stability without compromising its transfection 
efficiency, a diethylene glycol molecule was conjugated to peptide C6M1 at the N-terminus 
(Table 3.1). 
Table 3.1 Sequences and molecular weight of peptide 
Name Sequence MW (g/mol) Purity 
C6M1 Acetyl-RLWRLLWRLWRRLWRLLR-NH2 2689 96.3% 
DM1 DEG-RLWRLLWRLWRRLWRLLR-NH2 2835 95.7% 
 
3.3.1 The interaction of peptide with siRNAs 
For effective delivery of siRNA into cells, the anionic charge of siRNA molecules should 
be neutralized by peptides. To investigate the interaction of peptide with siRNA, increasing 
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amounts of peptides were mixed with siRNA that targeted the eGFP gene, and the complexes 
were analyzed by agarose gel electrophoresis assays. For our peptides C6M1 (Figure 3.1A) 
and DM1 (Figure 3.1B), the peptide/siRNA complexes started to form at a very low molar 
ratio of 1/1, as evidenced by a decrease in the intensity of the band representing a molar ratio 
of 1/1 relative to that representing a molar ratio of 0 (siRNA only). siRNA molecules were 
completely associated with C6M1 (Figure 3.1A) at molar ratios of 10/1 and above and with 
DM1 (Figure 3.1B) at molar ratios of 15/1 and above.  
These results support the hypothesis that the complete association of peptides with siRNA 
occurs when the molar ratio is greater than 6/1, as there are 7 positively charged arginine 
residues in 1 molecule of C6M1, as well as DM1, and there are 21 pairs of negatively charged 
oligonucleotides in one sieGFP molecule.   
Note that siRNA molecules were entirely complexed with DM1 at a higher molar ratio, i.e., 
a molar ratio of 15/1, than that for siRNA with C6M1. This finding suggests that although 
both peptides have the same number of positively charged arginine residues, more DEGylated 
peptides are required to form a complex with siRNA. One explanation is that the DEG shield 
builds a steric hindrance around complexes, which reduces the positive charge density of the 
peptides.  
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Figure 3.1 Agarose gel electrophoresis assay. A) Complexes C6M1/sieGFP and B) 
Complexes DM1/sieGFP, at molar ratios 0, 1/1, 5/1, 10/1, 15/1, 20/1, 30/1, and 40/1. 
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3.3.2 DEGylated peptide complexed siRNA is stable in the presence of serum 
Delivery systems should be able to shield and protect siRNA from degradation by 
nuclease enzymes in the cytoplasm and in serum. These enzymes have been reported to 
degrade DNA and RNA molecules into small ineffective fragments that lose their therapeutic 
effects [226-229]. To investigate the stability of two complexes in the presence of serum, an 
agarose gel electrophoresis assay was conducted.  
The complexes formed between peptide and siRNA could be dissembled by the addition 
of heparin (Figure 3.2). It has been reported that the addition of heparin would competitively 
disassociate DNA [230, 231] and siRNA [232, 233] from positively charged complexes. After 
the addition of heparin, the fluorescence intensity of siRNA did not change (Figure 3.2, lane 
2). However, when C6M1/siRNA and DM1/siRNA complexes were incubated with heparin 
for 30 min, a weak band appeared, indicating the release of siRNA (Figure 3.2, lane 4, and 
lane 6). Naked siRNA without peptides and peptide/siRNA complexes at a molar ratio of 30/1 
were incubated in 50% active FBS for various time periods (Figure 3.3). The naked siRNAs 
were completely degraded within 6 h (Figure 3.3, lane 4, and lane 5), while siRNA complexed 
with C6M1 and DM1 degraded much more slowly. siRNA was protected by peptide C6M1 
for 24 h (Figure 3.3, lane 6-9), but the siRNA was completely degraded within 48 h (Figure 
3.3, lane 10). Peptide DM1 achieved higher stability, which was able to protect siRNA for up 
to 72 h (Figure 3.3, lane 11-16).  
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Figure 3.2 Interaction of complexes with heparin. The complexes were formed at molar 
ratio 30/1, and eGFP targeting gene was used in the experiment. Lane 1: naked siRNA; Lane 2: 
siRNA incubated with heparin for 30 min; Lane 3 and 5: C6M1/siRNA and DM1/siRNA 
respectively; Lane 4 and 6: C6M1/siRNA and DM1/siRNA incubated with heparin for 30 min, 
respectively. 
 
After 6 hours, siRNA protected by C6M1 was partially degraded (Figure 3.3, lane 8-10), 
as evidenced by its decreased band intensity. It is worth noticing that, within 48 hours, there 
was no significant change in the band intensity of siRNA protected by DM1 (Figure 3.3, lane 
11-16).  
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Figure 3.3 Serum stability of complexes in the presence of 50% serum v/v. The complexes 
were formed at molar ratio 30/1, and eGFP targeting gene was used in the experiment. 
Heparin was added to each well except lane 1. Lane 1: naked siRNA; Lane 2 and 3: 
C6M1/siRNA and DM1/siRNA after 30 min without addition of serum, respectively; Lane 4 
and 5: naked siRNA incubated with serum for 2 h and 6 h; Lane 6 – 10:  C6M1/siRNA 
incubated with serum for 2 h, 6 h, 12 h, 24 h, and 48 h; Lane 11 – 16: DM1/siRNA incubated 
with serum for 2 h, 6 h, 12 h, 24 h, and 48 h. 
 
The results presented here suggest that the DEGylation of peptide C6M1 can improve its 
ability to protect siRNA against degradation by serum nucleases and enzymes. The DEG layer 
around the complexes might sterically shield siRNA molecules against surrounding molecules. 
It has been reported that polyethylene glycol plays an important role in stabilizing the 
structure of gene delivery systems and in protecting the siRNA vector from nuclease attack 
[234]. Here, we have shown that peptides conjugated with a shorter form of ethylene glycol, 
i.e., diethylene glycol, can also protect siRNA from degradation and prolong its incubation 
time within serum-containing medium. This finding suggests a promising in vivo application 
for peptide-assembled siRNA systems.  
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3.3.3 DEGylation can promote cell viability of cationic peptides 
Cell viability is one of the most important factors in selecting gene delivery systems. It has 
been reported that PEGylation can reduce the cytotoxicity of pDNA [235] and siRNA delivery 
systems. The effects of various peptide/siRNA complexes on CHO-K1 cell viability were 
tested using MTT assay. 
In Figure 3.4, neither C6M1/siRNA nor DM1/siRNA complexes caused cellular toxicity at 
molar ratios of 20/1 to 40/1. However, C6M1/siRNA complexes exhibited in vitro toxicity at a 
higher molar ratio of 80/1, resulting in only 69% viability, while DM1/siRNA complexes were 
not toxic at any molar ratios. It is very encouraging that little cytotoxicity was observed with 
DM1/siRNA complexes, which might be due to the reduced cationic density induced by DEG 
chains on the surface of complexes [236]. Highly positively charged C6M1/siRNA complexes 
at molar ratios of 80/1 might interact with negatively charged cell membranes and cause 
aggregation on the membrane surface, resulting in membrane rupture and cell death. Therefore, 
reducing the positive charge density by conjugating the DEG to peptides is a good way to 
reduce the cytotoxicity of cationic peptides as siRNA carriers.  
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Figure 3.4 Cell toxicity performed by MTT assay on CHO-K1 cells. Complexes 
C6M1/siGAPDH and DM1/siGAPDH at molar ratios of 20/1, 30/1, 40/1, 50/1, 60/1, 70/1, and 
80/1. 
 
 
3.3.4 Influence of DEGylation on cellular uptake efficiency 
One common concern of PEGylation is that it highly reduces charge density and thus 
decreases cellular uptake efficiency [222, 235]. To investigate the effects of DEGylation on 
siRNA delivery into cells, we used FACS to compare the cellular uptake potency of Cy-3 
labeled siRNA complexed with DM1 and C6M1 (Figure 3.5). 
As shown in Figure 3.5A, little naked siRNA was delivered into the cytoplasm. However, 
when siRNA was complexed with C6M1 and DM1 peptides, over 90% of siRNA was 
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delivered into the cells. The fluorescence intensity did not increase with the amount of peptide, 
and a molar ratio of 20/1 was sufficient to deliver siRNA into cells for both C6M1/siRNA and 
DM1/siRNA complexes. This result was in good agreement with the results obtained using the 
agarose gel assay, which demonstrated that free siRNA was fully complexed with peptides at 
a molar ratio of 20/1.  
The quantitatively analyzed results (Figure 3.5B) demonstrate that similar amounts of 
siRNA were delivered by C6M1 and DM1, suggesting that the DEGylation of the delivery 
system has little effect on cellular uptake efficiency. 
Figure 3.5C shows the typical cellular localization of the DM1/Cy-3 labeled siRNA 
complexes. A red fluorescence signal could be found in almost every cell, and the fluorescent-
labeled siRNA molecules were localized close to the nucleus, where siRNA molecules will 
bind to the RNA-induced silencing complex (RISC) and initiate RNA interference in the 
cytosol.  
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Figure 3.5 Cellular uptake of siRNA mediated by peptides on CHO-K1 cells. Cy-3 labeled 
siRNA were used in the experiment, and Cy-3 labeled siRNA incubated without transfection 
agent was used as negative control. Complexes peptide/siRNA were transfected with cells at 
molar ratios of 20/1 and 40/1. A) Fluorescence intensity measured by FACS, analyzed by 
FlowJo. B) Percentage of siRNA delivered into the cytoplasm. C) Fluorescence microscope 
imaging of cellular localization of DM1/siRNA complexes, scale bar = 100 µm 
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3.3.5 Knockdown efficiency of complexes formed by DEGylated peptide with siRNA in 
comparison with non-DEGylated peptide 
The silencing effect of peptide/siRNA complexes was evaluated on both mRNA and 
protein levels on different cell lines. First, we conducted RT-PCR on CHO-K1 cells to 
determine the level of GAPDH mRNA suppression mediated by peptides C6M1 and DM1 
(Figure 3.6). Scrambled siRNA was used as a negative control in each treatment group, and 
the peptide/scrambled siRNA complexes showed no gene silencing effects when compared to 
non-treated cells (Figure 3.6A). 
The relative amount of GAPDH mRNA inhibition was calculated as the peptide/siGAPDH 
divided by the peptide/scrambled siRNA (Figure 3.6B). Both the C6M1/siRNA and 
DM1/siRNA complexes demonstrated over 40% gene silencing efficiency, and their inhibitory 
effects increased as the molar ratio increased. It is worth noting that both the C6M1/siGAPDH 
and DM1/siGAPDH complexes inhibited GAPDH mRNA expression by more than 50% at a 
molar ratio of 40/1. 
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Figure 3.6 Inhibition of GAPDH activity on mRNA level through real time RT-PCR. 
Peptide/scrambled siRNAs were used as negative control in each group. A) GAPDH gene 
activity levels regulated with scrambled siRNA and siGAPDH. B) Percentage of GAPDH 
gene knockdown efficiency, calculated as: (1 – (peptide/siGAPDH expression) / (peptide/ 
scrambled siRNA expression)) x 100%. 
 
   71 
Next, the silencing effects of complexes were confirmed on the protein level using C166 
GFP cells that stably expressed the eGFP gene. Fluorescence intensity was measured using 
FACS and analyzed with FlowJo (Figure 3.7). Complexes of C6M1/sieGFP inhibited the 
eGFP protein by 35% at a molar ratio of 40/1 and complexes of DM1/sieGFP inhibited the 
eGFP by 31%. In contrast, cells treated with naked sieGFP did not exhibit any eGFP 
suppression compared to non-treated samples. 
 
Figure 3.7 Percentage of eGFP gene regulation on protein level through FACS. The results 
were calculated as: (1- (peptide/sieGFP expression) / (peptide/ scrambled siRNA expression)) 
x 100%. 
 
The suppression of GAPDH protein activity by peptide/siGAPDH and peptide/scrambled 
siRNA was measured using the KDalert assay kit (Figure 3.8). GAPDH is an enzyme 
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catalyzes the sixth step of glycolysis and break down glucose for energy and carbon molecules, 
and also involved in several non-metabolic processes, including transcription activation, 
initiation of apoptosis, ER to Golgi vesicle shuttling, and fast axonal, or axoplasmic transport. 
In the case of C6M1, complexes reduced GAPDH protein activity by 44% at a molar ratio 
of 20/1 and by 56% at a molar ratio of 40/1. In the case of DM1, complexes demonstrated a 
similar efficiency of gene knockdown, i.e., 40% and 61% suppression at molar ratios of 20/1 
and 40/1, respectively (Figure 3.8B).  
However, it is worth pointing out that C6M1/scrambled siRNA complexes caused a 
slightly reduction of GAPDH protein expression at a molar ratio of 40/1 (Figure 3.8A). This 
was the result of C6M1’s cytotoxicity on CHO-K1 cells compared to non-treated cells. No 
significant differences in GAPDH protein expression level were observed between cells 
treated by DM1/scrambled siRNA compared to non-treated cells. 
The GAPDH KDalert kit assay results corresponded well with RT-PCR results, which 
showed gene knockdown at the mRNA level (Figure 3.6), and the cytotoxicity data (Figure 
3.4).  
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Figure 3.8 Inhibition of GAPDH activity on protein level through real time KDalert assay 
kit. Peptide/scrambled siRNAs were used as negative control in each group. A) GAPDH gene 
activity levels regulated with scrambled siRNA and siGAPDH. B) Percentage of GAPDH 
gene knockdown efficiency, calculated as: (1 – (peptide/siGAPDH expression) / (peptide/ 
scrambled siRNA expression)) x 100%. 
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3.3.6 DEGylation on peptides facilitates RNAi efficiency in the presence of high serum 
concentration 
In serum-free medium, the complexes formed by DM1 exhibited a similar level of 
knockdown efficiency as complexes formed by C6M1. To study the effects of serum on 
transfection efficiency, we evaluated gene-silencing efficacy on CHO-K1 cells in the presence 
of increasing amounts of serum (Figure 3.9).  
The knockdown efficacies of C6M1/siRNA and DM1/siRNA were comparable at low 
serum concentration, i.e., 10% of serum, resulting in a reduction of GAPDH protein activity to 
approximately 50%. However, C6M1/siRNA gradually lost its knockdown capability as the 
proportion of serum in the medium increased. In the presence of 50% serum, the knockdown 
efficiency of C6M1/siRNA decreased to 15%, causing 2-fold less suppression of GAPDH 
protein activity than DM1/siRNA. Both C6M1/siRNA and DM1/siRNA lost their knockdown 
capability when the proportion of serum reached 90%.  
The promising results shown above demonstrate that DEGylation might provide 
complexes with steric protection to some extent, thus decreasing the ability of complexes to 
interact with serum components, as previously reported for PEGylation [217, 218]. The 
presence of massive amounts of albumin in serum has been reported to be the main inhibitor 
of both DNA [237, 238] and siRNA gene delivery [219, 220]. Negatively charged albumin 
would compete with siRNA for binding to the positively charged peptides, resulting in the 
dissociation of the complexes and the degradation of released siRNA [220].  
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Figure 3.9 Inhibition of GAPDH protein activity in the presence of serum through real 
time KDalert assay kit. Complexes were formed at molar ratio 40/1, and peptide/scrambled 
siRNAs were used as negative control in each group.  
  
   76 
3.4 Conclusion 
RNAi therapy is one of the most promising methods for the treatment of gene-related 
diseases. However, its application is limited in vivo due to the lack of the efficient and safe 
delivery, where the interactions between siRNA and serum components are a major cause for 
siRNA degradation during the delivery process [212-214]. To overcome the low efficiency of 
RNAi caused by serum, we modified our peptide carrier by conjugating it to a short ethylene 
glycol, i.e., DEG. The DEG-modified peptide/siRNA complexes enhanced cell viability and 
did not compromise RNAi efficiency. Our data revealed that the peptide conjugated with DEG 
improved serum resistance while maintaining sufficient gene silencing efficiency. Hence, 
DEGylated peptide/siRNA complexes may be a promising gene delivery method for in vivo 
gene therapy application. 
Despite the improved serum stability, the silencing efficiency of siRNA delivered by 
C6M1 and the modified DM1 ranged from 40% to 60%, and the less efficient knockdown 
ability might be due to the entrapment of siRNA in endosome/lysosome vesicles. Therefore, 
designing new sequences to enhance the endosomal escape of the complexes is required. 
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Chapter 4  
A novel peptide for efficient siRNA delivery in vitro and 
therapeutics in vivo 
 
4.1 Introduction 
As discussed previously in Chapter3, the application of siRNA has been limited by the 
anionic nature, relatively large molecular weight, and poor cellular uptake of siRNA 
molecules [88]. Thus, the development of efficient and safe delivery systems for siRNA has 
been an important area of research [23]. A variety of delivery strategies have been developed 
[24], and several strategies stand out. One approach that has attracted wide interest is the use 
of cell-penetrating peptides (CPPs). CPPs are a class of cationic and/or amphipathic peptides 
that can deliver siRNA as well as a wide range of small therapeutic molecules for both in vitro 
and in vivo applications [155, 156, 247].  
To efficiently condense and deliver siRNA, a CPP must have a positive charge [248, 249]; 
at least eight positive charges are needed for the efficient internalization of cell penetrating 
peptides [250]. However, excessive positive charges have been reported to cause tissue and 
cellular toxicity [251]. The use of a nuclear localization sequence (NLS) provides a solution to 
this dilemma. NLSs are short peptides that can be transported to the nucleus and have fewer 
than eight positive charges. The first discovered NLS, from simian virus 40 (SV40), is the 
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sequence PKKKRKV , which has been adopted directly in peptide sequence design for 
efficient siRNA delivery. For example, MPF (GLAFLGFLGAAGSTMGAWSQPKKKRKV) 
was derived from SV40 [253]. 
Based on SV40, we designed a series of amphiphilic peptides composed of a variant of the 
NLS and a hydrophobic block. The NLS has been modified to PKPKRKV by the single 
mutation of a lysine residue in SV40 to a proline residue, which aims to limit nuclear 
translocation and enable the rapid release of the cargo in the cytoplasm [253]. Because only 
four amino acids in the NLS variant are positively charged at pH 7, we conjugated the 
sequence PKPKRKV to a hydrophobic moiety to obtain an amphipathic version of CPP for 
good cellular uptake properties. 
Instead of a hydrophobic peptide sequence, we adopted stearic acid as the hydrophobic 
moiety in our peptides. Stearic acid has been proven to have a high affinity with the cell 
membrane , and the stearylation of cell-penetrating peptides has been reported to increase the 
transfection efficiency of both plasmid DNA and siRNA, e.g., STR-R8, STR-(RxR)4, and 
STR-CH2R4H2C [254-256]. The amino acid histidine was incorporated as a linker, i.e., HHH. 
Histidine is a pH-sensitive amino acid and can be protonated at low pH. Through the 
introduction of histidine moieties, peptides can act as a proton sponge and disrupt endosomal 
membranes , resulting in the release of siRNA complexes into the cytosol [258].   
In this study, we explored a group of five different peptides derived from PKPKRKV for 
their ability to form siRNA complexes and mediate gene silencing. We revealed that the 
incorporation of stearic acid and an NLS variant with a selected length of histidine residues 
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leads to improved transfection efficiency. To investigate the gene-silencing efficiency of the 
complex, we utilized RT-PCR to examine the knockdown efficiency induced by our peptides 
with siRNA complexes at the mRNA level. The in vitro cytotoxicity was carried out on 
Human lung cancer cell line (A549, ATCC CCL-185) with an MTT assay before conducting 
in vivo experiments. The results showed that the complexes of siRNA formed with peptide 
STR-HK were more efficient and displayed lower cytotoxicity than those with peptide H0K, 
HK, STR-H0K and STR-H6K. The in vivo anti-tumor effect of STR-HK/siRNA was 
determined on a xenograft mouse tumor model. Our results showed that the peptide STR-HK 
could greatly enhance the internalization of siRNA molecules, achieving a silencing efficiency 
of 78% in vitro and an inhibition rate of 63% in vivo without causing toxicity effects.  
This Chapter is based on the work published in Acta Biomaterilia, with authorship as: Ran 
Pan, Wen Xu, Feng Yuan, Dafeng Chu, Yong Ding, Baoling Chen, Mousa Jafari, Yongfang 
Yuan, Pu Chen. 
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4.2 Materials and methods 
4.2.1 Preparation of complexes  
Synthesized by CanPeptide Inc (Quebec, Canada), peptides were dissolved in RNase free 
water (Thermo scientific, Ottawa, Canada) at a concentration of 1 mM, followed by probe 
sonication for 10 min, and were stored at -20°C. Synthesized by Sigma, siRNA targeting at the 
B-cell lymphoma 2 (Bcl-2) gene were dissolved in RNase free water at a concentration of 50 
µM, and were store at -80°C.   
The peptide/siRNA complexes were prepared in RNase free water for characterization 
experiments, and were prepared in Opti-MEM (Invitrogen, Carlsbad, CA, USA) for 
transfection experiments. The peptide/siRNA complexes were prepared at different molar 
ratio ranged from 1/1 to 80/1 depending on the designed experiment, by slowly manually 
mixing the peptide solution into siRNA solution with pipette. The complexes were incubated 
at room temperature for 30 min before conducting experiments.   
Lipofectamine 2000, purchased from Life Technologies, was used as positive control in 
experiments. The lipo 2000/siRNA complexes were prepared in Opti-MEM for transfection 
experiments, by slowly manually mixing the lipo 2000 solution into siRNA solution with 
pipette. The ratio of lipo 2000/siRNA remains unknown, since the concentration of lipo 2000 
was not revealed by the manufacturer. The amount of lipo 2000 was 1.0 µl/well for 24-well 
plate, and 0.25 µl/well for 96-well plate, according to the manufacturer’s instructions. 
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4.2.2 Sequence of siRNAs 
The siRNA targeting Bcl-2 oncogene was synthesized by Sigma, with a sense sequence of 
5’-GGT GGG GTC ATG TGT GTG G-dTdT, and antisense sequence of 5’-CGG TTC AGG 
TAC TCA GTC ATC C-dTdT. The SilencerTM Cy3-labeled GAPDH siRNA was purchased 
from Ambion, used in fluorescence microscopy and Fluorescence Activated Cell Sorting 
(FACS). The eGFP siRNA, used in agarose gel electrophoresis and ribogreen assay, was 
purchased from Dharmacon with an extinction coefficient of 362408 L/mol cm. The sense 
sequence of eGFP siRNA was 5’-GAC GUA AAC GGC CAC AAG UUC-dTdT, and 
antisense sequence was 5’-ACU UGU GGC CGU UUA CGU CGC-dTdT. The negative 
control siRNA with scrambled sequence used in the experiment was purchased from Ambion. 
4.2.3 Gel electrophoresis assay 
The interaction of peptide/siRNA complexes was investigated using agarose gel 
electrophoresis assay. Peptides were mixed with siRNA to form peptides/siRNA complexes as 
described above with a final amount of 200 ng siRNA per well. The complexes were 
incubated at room temperature for 30 min before being loaded onto a 1.2% w/v agarose gel 
labeled with ethidium bromide in TBE buffer and run at 50 V for 60 min.  
4.2.4 RiboGreen assay 
The amounts of siRNA were quantified by ribogreen assay (Quanti-ITTM RiboGreen, 
Invitrogen, USA). Peptides were mixed with siRNA to form peptides/siRNA complexes as 
described above. According to manufacturer’s instruction, the complexes solution and 
ribogreen solution was prepared separately, and the aqueous working solution of ribogreen 
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assay was slowly added into each sample manually. Each sample was incubated at room 
temperature for 3 min before measured on UV-Vis spectrometer (Ultrospec 4300 Pro, GE, 
Canada) with excitation at 480 nm and the emission at 520 nm.  
4.2.5 Fourier Transform Infrared (FTIR) spectroscopy 
The secondary structure of STR-HK was investigated by a Vertex 70 STIR spectrometer 
(Bruker Optics, Inc., Billerica, MA, USA) equipped with a liquid nitrogen cooled MCT 
detector. STR-HK was dissolved in water with different concentration. The spectra of peptides 
were recorded in the range of 4000-400 cm-1 at a spectra resolution of 4 cm-1, and were 
analyzed with OPUS 5.5 software (Bruker Optics, Inc., Billerica, MA, USA).  The absorption 
spectrum was analyzed between 1700 cm-1 and 1600 cm-1. 
4.2.6 Particle size 
The hydrodynamic diameter of peptide/siRNA complexes were determined on a Zetasizer 
Nano ZS (Malvern Instruments, U.K.) equipped with a 4 mW He-Ne laser operating at 633 
nm. The complexes were prepared as described above at a molar ratio of 40/1, with a final 
siRNA concentration of 100 nM. The light intensity of complexes were collected at an angle 
of 173°.  
4.2.7 Atomic force microscopy (AFM) 
The morphology of STR-HK/siRNA complexes was observed by AFM (Dimension Icon, 
Bruker, California, USA) at a molar ratio of 40/1. The complexes were prepared as described 
above, and were loaded on a freshly cleaved-mica surface. The samples were then washed 
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twice and allowed to air-dry overnight. Standard tips (Bruker, California, USA) were used. 
Samples were visualized in peak force quantitative nanomechnics (PeakForce QNM) mode, an 
extension of peak force tapping mode, at 1.0 Hz scanning rate. The scanned image was 
collected from a 5 x 5 µm area. 
4.2.8 Transmission electron microscopy (TEM) 
The morphology of STR-HK/siRNA complexes was acquired by transmission electron 
microscopy (TEM, Philips CM10 TEM, Amsterdam, the Netherlands) at a molar ratio of 40/1. 
The complexes were prepared as described above with 300 nM of siRNA in 10 ml samples, 
and were applied to a 400 mesh Formva coated copper grid (Canemco-Marivac, Canton de 
Gore, Canada). The samples were washed 5 times with RNase free water and dried overnight, 
and then stained with uranyl acetate (Electron Microscopy Sciences, Hatfiled, USA).  
4.2.9 Cell culture and peptide mediated siRNA transfection 
Transfection experiments were conducted using Human lung cancer cell line (A549, 
ATCC CCL-185). The A549 cells were maintained in F-12K medium (Thermo scientific, 
Ottawa, Canada) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Oakville, 
Ontario, Canada) at 37°C in 5% CO2. Before transfection, A549 cells were seeded in 24-well 
plates with a confluence of 40,000 cells/well or 60,000 cells/well, and in 96-well plates with a 
confluence of 7,500 cells/well. After incubating at 37°C for 24 hours, cells were rinsed with 
phosphate buffered saline (PBS), which was then replaced with Opti-MEM. The STR-
HK/siRNA complexes were prepared as described above, diluted in Opti-MEM to a final 
concentration of 50 nM siRNA and then added to each well. After the cells were incubated at 
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37°C for 4 hours, medium containing FBS was added to obtain a final concentration of 10% 
FBS. 
4.2.10 Cytotoxicity of complexes 
The cytotoxicity of peptide/siRNA complexes was evaluated using 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, purchased from Sigma. 
A549 cells were seeded in 96-well plates at 7,500 cells/well and transfected with 
peptide/siRNA complexes, as described above. After 48 hours, cells were rinsed with PBS, 
and 100 µL of MTT solution (5 mg/mL in PBS) was added to each well. After 2 hours of 
incubation at 37°C, 100 µL of solubilization solution, composed of 10% Triton X-100 (Sigma) 
plus 1% HCl (Sigma) in anhydrous isopropanol (Invitrogen), was added to each well to 
dissolve the formazan crystals. The optical densities were then measured at 570 nm with a 
microplate reader (FLUOstar Optima, BMG Labtech, Ortenberg, Germany). Cell viability was 
calculated as the optical density of each sample divided by the optical density of untreated 
controls. All measurements were performed in triplicate. 
4.2.11 Fluorescence microscopy  
    The cellular uptake efficiency of complexes was studied by fluorescence microscopy. 
A549 cells were seeded in 24-well plates at 60,000 cells/well, and transfected with 
peptide/Cy-3-labeled GAPDH siRNA complexes 24 hours later, as described above. After 4 
hours of incubation at 37°C, cells were rinsed with PBS and incubated in 15 U/ml heparin 
medium for 20 min. This step was repeated 3 times. Cells were then washed twice with PBS, 
and fixed with 500 µl/well of 4% PFA in PBS at 37°C. After 30 min, the fixation PBS was 
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aspirated, and the cells were washed twice with PBS before they were covered with 
Fluoroshield with DAPI mounting medium (Sigma-Aldrich, Oakville, Ontario, Canada). The 
samples were visualized on a Zeiss Observer Z1 microscope with a 40x objective lens. Images 
were analyzed using AxioVision software. All measurements were performed in triplicate. 
4.2.12 Confocal laser scanning microscopy (CLSM)  
    A549 cells were seeded in a Nunc Lab-Tek II 4-well chambered coverglass (Thermo 
scientific, Ottawa, Canada) at 80,000 cells/well, and transfected with peptide/Cy-3-labeled 
GAPDH siRNA complexes 24 hours later, as described above. After incubation at 37 °C, 75 
nM/well of Lysotracker Green (Life Technology, Carlsbad, USA) were added into the 
medium and incubated for 1 hour. Cells were then washed with 15 U/ml heparin medium for 3 
times in one hour at 37 °C, and rinsed twice with PBS. 500 µL of medium were added into 
each well, with 1 drop of NucBlue Live ReadyProbes Reagent (Life Technology, Carlsbad, 
USA). Carl Zeiss LSM 700 confocal microscope (Zeiss, Jena, Germany) was used to visualize 
the cells. The microscope was equipped with Plan-Apochromat 20x/0.8 NA objective lens. 
The images were analyzed with Olympus FluoView FV1000 software. 
4.2.13 Uptake efficiency of complexes 
The cellular uptake efficiency of complexes was quantified by flow cytometry (type BD 
Biosciences, BD FACS Vantage SE Cell Sorter, USA). A549 cells were seeded in 24-well 
plates at 60,000 cells/well, and transfected with peptide/Cy-3-labeled siRNA complexes 24 
hours later, as described above. After 4 hours of incubation at 37°C, cells were rinsed with 
PBS and incubated in 15 U/ml heparin medium for 20 min. This step was repeated 3 times. 
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Cells were then washed twice with PBS, detached from the plate with 0.25% trypsin/EDTA, 
and then collected in the suspension of 4% PFA in PBS. The collected samples were analyzed 
by fluorescence acquired cell sorting (FACS), and the data were analyzed by Flowjo software. 
All measurements were performed in triplicate. 
4.2.14 Bcl-2 silencing assay at mRNA level 
The efficiency of Bcl-2 siRNA interference was evaluated using real time RT-PCR that 
shows the gene knockdown on mRNA level. The sequences of Bcl-2 primers adopted in this 
study were: 5’-GGTGGGGTCATGTGTGTGG-3’ (F), and 5’-
CGGTTCAGGTACTCAGTCATCC-3’ (R). A549 cells were seeded in 24-well plates and 
transfected with peptide/siRNA complexes 24 hours later, as described above. After 48 hours, 
total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and the 
RNA concentration was measured using Nanodrop (Nanodrop spectrophotometer ND-1000, 
Thermo scientific, Ottawa, Canada). RNA was then reverse transcribed into cDNA using Bio-
Rad iScript cDNA synthesis kit (Bio-Rad Laboratories, Ontario, Canada). RT-PCR was 
performed using the Mx3005P™ Real Time PCR System (Agilent Technologies, Wilmington, 
DE, USA) with Brilliant II Fast SYBR Green QPCR Master Mix (Agilent Technologies), 
according to the manufacturer’s instructions. The data was normalized to cyclophilin genes, 
with primer sequences as: 5’-GGTGATCTTTGGTCTCTTCGG-3’ (F), and 5’-
TAGATGCTCTTTCCTCCTGTG-3’ (R). All measurements were performed in triplicate. 
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4.2.15 In vivo experiment 
    To evaluate the efficacy the antitumor activity of STR-HK/siRNA complexes, six-
week-old male BALB/c nude mice were used as mouse xenograft tumor model, with eight 
mice involved in each group. Animal experiments were carried out with the NIH Guide for the 
Care and Use of Laboratory Animals, provided by Shanghai Jiao Tong University, Shanghai, 
China. Obtained from the B&K Universal Group Limited (Shanghai, China), all mice were 
maintained under 12 hours light/dark cycles at 25°C with 60±10% humidity. The mice were 
inoculated subcutaneously with 5×106 A549 cells at the right armpit to generate the xenograft 
tumor model. When the tumor volume reached 100-200 mm3, STR-HK/siRNA targeting Bcl-2 
oncogene complexes was injected directly into the tumor at a molor ratio of 60:1. Total nine 
treatments per mouse were administered at a dose of 4 ug siRNA/mouse, every three days. 
The diameters of tumors and the body weight of mouse were measured every day. All mice 
were sacrificed on day 27, and and the tumor volume was calculated as follows: tumor 
volume=0.5×(width)2×length.  
4.2.16 Western blot 
    Western blot assay were used to analyze Bcl-2 protein expression in tumor tissue. 
According to the manufacturer’s instructions, the proteins were extracted using a total protein 
extraction kit (Kangchen Biotechnology, Shanghai, China). Protein samples were separated 
by 12% SDS-PAGE gels and then transferred to nitrocellulose (NC) membranes. After 
blocking with blocking buffer for 2 hours, the membranes were incubated with polyclonal 
rabbit anti-Bcl-2 (Santa Cruz, California, USA) with a ratio of 1:1000 overnight at 4 °C. 
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Horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG (Kangchen Biotechnology, 
Shanghai, China) was used as a secondary antibody with a ratio of 1:2000 for 2 hours. The 
bound secondary antibody was detected by enhanced chemiluminescence (Pierce 
Biotechnology, Rockford, IL, USA). GAPDH (Kangchen Biotechnology, Shanghai, China) 
was used as an internal standard.  
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4.3 Results and Discussion 
4.3.1 Characterization and interaction of the peptides with siRNA  
The peptides were designed to comprise a modified NLS block, which has 3 positive 
charges and 0, 3 or 6 histidine residues. Optionally, stearic acid was incorporated at the N-
terminus of the peptides, as shown in Table 4.1.  
Table 4.1 Sequences and molecular weight of peptides 
Name Sequence MW Purity 
H0K Acetyl-PKPKRKV-NH2 895.4 97.3% 
HK Acetyl-HHHPKPKRKV-NH2 1304.7 99.4% 
STR-H0K Stearyl-PKPKRKV-NH2 1117.7 94.7% 
STR-HK Stearyl-HHHPKPKRKV-NH2 1529.0 96.2% 
STR-H6K Stearyl-HHHHHHPKPKRKV-NH2 1940.1 95.1% 
 
 
The sizes of the peptide/siRNA complexes were examined by dynamic light scattering at 
peptide to siRNA molar ratios of 20/1, 40/1, 60/1 and 80/1. As shown in Table 4.2, the 
average diameter of the complexes ranged from 47 nm – 184 nm, which has been reported as 
the optimal size range for nanoparticles internalized by cells [259]. Preferably, the size of 
carrier/siRNA complexes should be less than 200 nm to ensure optimal diffusion through 
tumor tissue by the enhanced permeation retention effect (EPR), and to reduce the recognition 
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and removal by phagocytic cells in vivo. Figure 4.1 shows the typical morphology of the STR-
HK/siRNA complexes as visualized by atomic force microscopy (AFM) and transmission 
electron microscopy (TEM) at a molar ratio of 40/1. Although some aggregated complexes are 
observed in both images, the main population of the complexes was characterized with a 
width of approximately 40-120 nm, consistent with the DLS results. Additionally, the AFM 
and TEM images revealed the round shapes of the complexes resulting from the co-assembly 
of STR-HK and siRNA molecules.  
Table 4.2 Particle sizes of peptides with siRNA complexes at different molar ratios 
Name 
MR20 
(nm) 
PDI 
MR40 
(nm) 
PDI 
MR60 
(nm) 
PDI 
MR80 
(nm) 
PDI 
H0K 151 > 0.5 144 0.48±0.09 129 0.33±0.05 134 0.29±0.07 
HK 184 > 0.5 167 0.35±0.11 120 0.22±0.17 131 0.21±0.03 
STR-H0K 147 0.31±0.17 129 0.31±0.06 101 0.27±0.02 97 0.23±0.04 
STR-HK 132 0.24±0.04 115 0.29±0.05 88 0.18±0.01 64 0.12±0.03 
STR-H6K 124 0.29±0.03 109 0.22±0.03 76 0.17±0.05 47 0.19±0.02 
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Figure 4.1 Morphology and size investigation of STR-HK/siRNA complexes. A: A typical 
AFM image of STR-HK/siRNA complexes at MR 40, with a 5 µm x 5 µm scan.  B: TEM 
image of STR-HK/siRNA complexes at MR 40, with a scale bar of 100 nm. 
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The secondary structure of the peptide STR-HK was studied by Fourier Transform 
Infrared (FTIR) spectroscopy in the range of 1700-1600 cm-1, which is the spectral region 
most sensitive to peptide secondary structure, where the amide I band is located. The peaks at 
~ 1630 cm-1 and ~ 1690 cm-1 were assigned to β-sheet structures, and the peaks at ~ 1670 cm-1 
represent β-turn structures [260]. As shown in Figure 4.2, STR-HK showed one peak at 
approximately 1630 cm-, and another peak at 1670 cm-1, suggesting the presence of a 
combination of β-sheet and β-turn structures. When the concentration of STR-HK was 
increased, the intensities of the peaks increased, while the locations of the peaks remained the 
same, suggesting that the secondary structures were stable and independent of concentration. 
 
Figure 4.2 FTIR spectra of peptides STR-HK of the amide I region with concentration 
different concentrations.  
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To investigate the complexes formed between the peptides and siRNA, a RiboGreen assay 
was applied to quantitatively characterize the interactions between the peptides and siRNA 
(Figure 4.3A). The strong fluorescence of RiboGreen intercalates with free siRNA, and the 
binding capacity of siRNA can be detected and calculated based on the fluorescence of 
RiboGreen.  At a pH of 7, arginine and lysine residues are positively charged and can interact 
with the phosphate groups on siRNA molecules through electrostatic interactions. There were 
four positively charged residues in each peptide molecule, i.e., three lysine amino acids and 
one arginine amino acid. The intensities of the complexes gradually decreased with an 
increasing molar ratio of peptides/siRNA, and the siRNA molecules were completely 
complexed with peptides HK, STR-H0K, STR-HK, STR-H6K at a molar ratio of 15/1, and 
with peptide H0K at a molar ratio of 20/1.  
Figure 4.3B shows a typical agarose gel electrophoresis assay for the STR-HK/siRNA 
complexes at different molar ratios. In Figure 4.3B, the peptide/siRNA complexes started to 
form at a very low molar ratio (MR) of 1/1, as evidenced by the decrease in the band intensity 
relative to that for the molar ratio of 0 (siRNA only). The siRNA molecules were completely 
associated with STR-HK at MR 15 and above, as there was no band for free siRNA detected.  
Ideally, siRNA molecules should completely bind to peptides when the molar ratio is 
greater than 11/1, since in peptide sequence PKPKRKV there are four positively charged 
residues in one molecule at pH 7, which consisted of three lysine residues and one arginine 
residue. There were 21 pairs of negatively charged nucleotides in one siRNA molecule, which 
in theory, could be condensed with these peptides at a molar ratio of approximately 11/1. The 
experimental results suggest that the peptide/siRNA complexes can be used in transfection 
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experiments with a molar ratio higher than 15/1 to ensure complete siRNA complexation. In 
this study, we prepared the complexes in pH 7 environments, and molar ratios of 20/1, 40/1, 
60/1 and 80/1 were adopted in the following cellular experiments.   
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Figure 4.3 Interactions between peptides and siRNA molecules. A: siRNA binding 
capacity, measured by ribogreen assay with five peptides/siRNA compelxes: H0K/siRNA, 
HK/siRNA, STR-H0K/siRNA, STR-HK/siRNA, and STR-H6K/siRNA: with molar ratios of 0, 
5/1, 10/1, 15/1, 20/1, 40/1, 60/1, and 80/1; B: an agarose gel electrophoresis assay of STR-
HK/siRNA complexes: with molar ratios of 0, 1/1, 5/1, 10/1, 15/1, 20/1, 40/1, and 60/1. 
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4.3.2 Knockdown efficiency of the HK peptide/siRNA complexes in vitro 
To gain insight into the potential use of our peptides as a delivery agent, we conducted 
transfection experiments on A549 cells and analyzed the results with RT-PCR (Figure 4.4). 
The Bcl-2 gene was chosen to evaluate the gene-silencing efficacy of the peptide mediated 
siRNA transfection. The complexes of scrambled siRNA with peptides (negative control) and 
the naked Bcl-2 siRNA without peptides showed no knockdown of the Bcl-2 gene at the 
mRNA level. Comparing the peptides at different molar ratios, the STR-HK/siRNA 
complexes induced the highest silencing effect of 78% at a molar ratio of 40/1 (Figure 4.4). 
The complexes of siRNA with STR-H6K induced a silencing efficiency of 36%±4.6% at 
MR60, while the complexes of siRNA with H0K, HK, STR-H0K showed a less than 30% 
silencing efficiency. 
    The STR-HK/siRNA complexes reduced the mRNA level of the Bcl-2 gene to a lesser 
extent than did lipo2000/siRNA; i.e., 78%±3.4% of STR-HK/siRNA at MR40 and 89%±2.2% 
of lipo2000/siRNA. However, it was shown above that the high transfection efficiency of 
lipo2000/siRNA is associated with high cytotoxicity (Figure 4.7, shown in 4.3.4). Comparing 
the cell viability profiles of lipo 2000 with those of STR-HK, there was a more than 30% 
reduction for the lipo2000/siRNA complexes, while there was little toxicity from STR-
HK/siRNA at the molar ratios used for the knockdown experiments.  
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Figure 4.4 Inhibition of Bcl-2 activity on mRNA level through real time RT-PCR, with 
siRNA conc. = 50 nM/well. Peptide/scrambled siRNA complexes were used as negative 
control in each group. Lipofectamine 2000 was used as a positive control. Percentage of Bcl-2 
gene knockdown efficiency, calculated as: (1 – (peptide/siRNA targeting Bcl-2 gene 
expression) / (peptide/scrambled siRNA expression)) x 100%.  
 
4.3.3 Cellular uptake and colocalization of the peptide/siRNA complexes  
We further evaluated the ability of our peptides to deliver siRNA into cells. To eliminate 
the effect of the complexes attached to the surfaces of cells [261], 15 U/ml heparin in Opti-
MEM was used to wash the cells three times at 37°C to ensure that all the visible siRNA 
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molecules were localized inside the cells [147]. The uptake efficiency of the Cy-3 labeled 
siRNA/HK peptide complexes was examined at different molar ratios with fluorescence-
activated cell sorting (FACS) (Figure 4.5A). 
The uncomplexed siRNA molecules could not be delivered into the cells, while the uptake 
efficiency of the peptide/siRNA complexes increased significantly. The uptake efficiency of 
the STR-HK/siRNA complexes at MR 40 was approximately 20% higher than that of the 
lipo2000/siRNA. However, a lower uptake efficiency of 20%±2.1% was observed in the 
treatment with the STR-HK/siRNA complexes at MR 20 because the positive charge was 
involved in the interaction with siRNA, and the net positive charge was insufficient to interact 
with the cell membranes [138]. The complexes of Cy-3 labeled siRNA with H0K or HK 
exhibited a 15% cellular uptake rate, while the uptake efficiency increased to 20% - 65% after 
conjugating with stearic acid, i.e., in the complexes STR-H0K, STR-HK and STR-H6K. These 
results suggested that stearic acid was essential for the cellular internalization of the 
peptide/siRNA complexes and that the addition of histidine as a linker was necessary; i.e., the 
STR-HK/siRNA complexes showed improved uptake efficiency compared with the 
complexes without histidine, i.e., STR-H0K/siRNA. However, the increased length of the 
histidine residues resulted in a decreased cellular internalization of the peptides, i.e., of STR-
H6K/siRNA relative to STR-HK/siRNA. Furthermore, the low cellular internalization 
efficiency of the STR-H6K/siRNA complexes might explain their limited gene-silencing 
performance. 
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Figure 4.5B shows the typical cellular uptake and localization of the STR-HK/Cy-3 
labeled siRNA complexes. As expected, the uncomplexed Cy3-labeled siRNA could not be 
internalized into the cells (Figure 4.5B1), in accordance with previous results (Figure 4.5A). 
siRNA internalization occurred only in the presence of STR-HK or lipo2000. A red 
fluorescence signal could be found in almost every cell and was localized around the nucleus. 
Moreover, the effects were more pronounced with peptide STR-HK at MR 40 (Figure 4.5B3) 
than with lipo2000/siRNA (Figure 4.5B2). The fluorescent-labeled siRNA molecules were 
localized close to the nuclear membrane instead of in the nucleus (Figure 4.5) because siRNA 
molecules will bind to the RNA-induced silencing complex (RISC) and initiate RNA 
interference in the cytosol.  
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Figure 4.5 Uptake efficiency of peptide/siRNA complexes on A549 cells, with siRNA 
conc. = 50 nM/well. A: fluorescence intensity of internalized complexes measured by FACS, 
analyzed by flowjo. B: fluorescence microscopy of STR-HK/siRNA complexes, the blue solid 
circles: cell nucleus dyed by DAPI; red dots: cy-3 labeled siRNA. B1: siRNA only treated 
cells; B2: lipo 2000/siRNA treated; B3: STR-HK/siRNA at MR 40. 
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To observe subcellular localization, A549 cells were treated with peptide/siRNA 
complexes and visualized with confocal microscopy. Figure 4.6 showed a punctual 
distribution pattern of peptide/siRNA complexes, which was in accordance with the punctual 
pattern of endosomal/lysosomal vesicles as labeled with Lysotracker Green. At 3h, the 
colocalization percentage of siRNAs with endosome/lysosome vesicles were calculated as 
87%, visualized as yellow fluorescent spots in Figure 4.6A. This suggested that the 
peptide/siRNA complexes were internalized within three hours through endocytic pathway. 
The same colocalization pattern can be visualized clearly in the enlarged cellular image. 
Endosomal escape of siRNAs can be obsearved at 12 hours after treatment, shown in Figure 
4.6B, with the colocalization percentage decreased to 32%. 
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Figure. 4.6A 
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Figure 4.6B 
 
Figure 4.6 Intracellular localization of STR-HK/siRNA complexes on A549 cells, with 
siRNA conc. = 50 nM/well. Images were visualized by confocal microscopy, and 
pseudocolored for visualization: blue = DAPI; red = Cy-3 siRNA; green = LysoTracker Green. 
Co-localization of siRNA with the endosomal/lysosomal marker is in yellow. A: 3 hours 
incubation time; B: 12 hours incubation time. 
 
4.3.4 Cell viability in the presence of the peptide/siRNA complexes  
Safety is one of the most important factors for selecting gene delivery systems. To study 
the cytotoxicity of peptide/siRNA complexes, an MTT assay was used on A549 cells. The cell 
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viability profile shown in Figure 4.7A indicated that no cytotoxicity was induced by the 
siRNA complexes with peptides H0K, HK or STR-H0K. In addition, the cell viability was not 
significantly affected in the cells treated with STR-HK/siRNA or with STR-H6K/siRNA at 
MR20 and MR40. There was more than 90% viability at MR 20 and MR 40 after 48 hours of 
treatment with STR-HK/siRNA and STR-H6K/siRNA, which was higher than the cells treated 
with the lipo2000/siRNA complexes, which showed only 70% viability. The STR-HK/siRNA 
and STR-H6K/siRNA treatments at MR60 appeared to induce only slight cytotoxicity 
compared to the non-treated cells.  
Increasing the amounts of STR-HK and STR-H6K greatly influenced the cell viability. At 
MR80, more than half of the cells died after 48 hours of treatment. A high positive charge 
density has been reported to result in toxicity because positively charged residues can interact 
with negatively charged cell membranes and cause aggregation and rupture on the membrane 
surface . The reduced charge density in STR-HK corresponds to good cell viability results, as 
expected. This non-toxic nature is important to develop successful gene-silencing reagents and 
therapeutic agents for in vivo applications. The low toxicity shown here suggests that STR-HK 
is a safe transfection reagent. 
The cell viability of peptides only was shown in Figure 4.7B, which was relatively lower 
than the corresponding complexes. The reason for that might be there are more positive 
charges in peptides only, while the addition of siRNA molecules neutralizes the charges. 
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Figure 4.7 Cell toxicity performed by MTT assay on A549 cells, with siRNA conc. = 50 
nM/well. Lipofectamine 2000 was used as positive control. A: Peptide/siRNA complexes 
were tested with 4 different molar ratios: 20/1, 40/1, 60/1, and 80/1. B: Peptide only with 
addition of peptide amounts equivalent to corresponding complexes: 1 µM/well, 2 µM/well, 3 
µM/well, and 4 µM/well. (* vs non-treated group, p<0.05) 
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4.3.5 In vivo results with STR-HK/siRNA complexes 
siRNA shows great therapeutic potential as a cancer drug in mouse tumor models because 
of its ability to regulate the activity of oncogenes. In recent years, several studies have 
reported the in vivo application of liposomes as gene delivery agents [263, 264], while the 
application of peptide-mediated siRNA delivery for in vivo applications still remains a 
challenge, because of the complicated situation in the body, such as the presence of 
extracellular matrix barriers and the occurrence of serum degradation and immune responses. 
Therefore, in an effort to demonstrate its clinical potential, we investigated the antitumor 
activity of the STR-HK/siRNA complexes in a mouse xenograft tumor model.  
The Bcl-2 protein is an attractive target for gene therapy because it regulates the 
mitochondria-mediated apoptosis pathway [265]. Drugs designed to reduce the level of Bcl-2 
protein are expected to promote apoptosis and therefore inhibit tumor growth. 
To demonstrate their potential for in vivo applications, we investigated the antitumor 
activity of the STR-HK/siRNA complexes in a mouse xenograft Non-small cell line cancer 
A549 model. The results showed that STR-HK/siRNA at MR 60 could successfully suppress 
tumor cell proliferation throughout the experimental period (Figure 4.8A) while showing 
minimal toxicity (Figure 4.8D). Interestingly, the tumor treated with naked Bcl-2 siRNA also 
showed a decreased size (Figure 4.8). In addition, 62% of silencing efficiency was 
demonstrated in western blot results of STR-HK/siRNA treated group, while 30% of silencing 
efficiency was also shown in siRNA only group. The results are in accordance with other 
researchers on A549 xenograft mouse model , and other types of cancer cells [267]. The 
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cellular uptake of naked siRNAs in vitro was relatively low, compared with the uptake into 
tissues in vivo. The mechanisms remain unknown, but it might be due to the role of the 
complex extracellular matrices in tissues [267]. However, STR-HK/siRNA complexes clearly 
induced a better antitumor effects compared with naked siRNA group, shown from the 
western blot results. 
After 27 days of treatment, the tumor tissues were separated and weighed (Figure 4.8B and 
C). The average tumor volumes of the control group and the STR-HK/siRNA treated group 
were 1246 mm3 and 544 mm3, respectively, demonstrating that the tumor size was 
significantly reduced upon STR-HK/siRNA treatment. The tumor weight of the STR-
HK/siRNA treated group, 0.4714 g, was lower than that of the control group at 1.27 g and 
than that of the saline treated control group at 1.36 g, demonstrating a tumor inhibition rate of 
62.86% (Figure 4.8C). A lack of significant changes in body weight (Figure 4.8D) 
demonstrated that the STR-HK/siRNA complexes were relatively safe to use. No severe side 
effects were observed during the experimental periods. A western blot analysis indicated that 
there was a specific down regulation of the Bcl-2 protein in the STR-HK/siRNA treated group, 
while the housekeeping protein GAPDH remained unchanged (Figure 4.8E). In summary, 
STR-HK/siRNA can inhibit tumor growth with an inhibition rate of 62.8% through 
intratumoral injection in the xenograft mouse tumor model. No significant body weight 
decreases and no severe side effects were observed over the experimental periods, which 
suggest that the STR-HK/siRNA complexes are potentially safe for in vivo applications. 
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Figure 4.8 In vivo results of STR-HK, with 8 mice involved in each group. A: tumor 
volume of each group (* vs model group, p<0.05; ** vs model group and siRNA group, 
p<0.05); B: separated tumor of each group; C: tumor weight of each group; D: body weight of 
each group; E: Bcl-2 protein expression with western blot. 
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4.4 Conclusions 
    Small interfering RNA can inhibit the expression of specific genes and has considerable 
potential as a therapeutic agent for many diseases. The development of siRNA carriers with 
good efficiency and low toxicity is highly expected. In this study, we designed a series of 
peptides and investigated their use as potential siRNA delivery systems. The results revealed 
that the peptide STR-HK, a new amphiphilic, cationic peptide consisting of a modified NLS 
block and a stearic acid tail, could efficiently facilitate siRNA delivery. Together with results 
showing that STR-HK/siRNA possesses the ability to inhibit the expression of specific genes 
both in vitro and in vivo, we showed that STR-HK is a successful siRNA delivery carrier and 
may be used for siRNA therapeutics. 
Despite the successful tumor inhibition, peptide STR-HK and the STR-HK/siRNA 
complexes induced strong cytotoxicity in vitro with the increasing amounts of peptide, i.e., the 
cell viability of STR-HK/siRNA complexes dropped to 50% when the peptide concentration 
increased to 4 µM. Hence, the modification of peptide sequence and the designing of peptides 
with less cytotoxicity is highly required.  
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Chapter 5 
Evaluation of Newly Designed Cell Penetrating Peptides with 
Stearic Acid as siRNA Carriers 
 
 
5.1 Introduction 
As previously discussed in Chapter 3 and Chapter 4, the applications of siRNA depended 
on the development of delivery systems. In this chapter, we designed a family of cell-
penetrating peptides, which formed nano-complexes with siRNA through electrostatic 
interactions and mediated gene silencing on various cell lines.  
Based on the design principles, a selected small number of lysine residues were employed 
in the sequences, to provide positive charges to bind with the siRNAs while not inducing 
toxicity due to a high number of positive charges. Second, to overcome the lack of sufficient 
positive charges to cross the plasma membrane and based on the previous results from Chapter 
4 [268] and [269], we adopted stearic acid, which was reported to have a high affinity to the 
cell membrane. Moreover, we investigated the addition of a histidine group and valine group 
and the effects on their biological activities. In this chapter, we intended to determine which 
sequences could increase the gene silencing efficiency without inducing cytotoxicity. The 
physical chemistry properties of peptide/siRNA complexes were characterized and compared. 
   111 
The gene silencing efficiency of peptide/siRNA complexes was optimized and then studied in 
various cell lines. The cytotoxicity and immunogenicity of the complexes was also 
investigated. 
This Chapter is based on the work submitted to Journal of Physical Chemistry B, with 
authorship as: Ran Pan, Wen Xu, Danyang Zhao, Yong Ding, Sheng Lu, Lei Zhang, Pu Chen. 
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5.2 Materials and methods 
5.2.1 Preparation of complexes  
Synthesized by CanPeptide Inc (Quebec, Canada), peptides were dissolved in RNase free 
water (Thermo scientific, Ottawa, Canada) at a concentration of 500 µM, followed by probe 
sonication for 10 min, and were stored at -20°C. The peptide sequences were listed in Table 
5.1. Synthesized by Sigma, siRNA were dissolved in RNase free water at a concentration of 
50 µM, and were store at -80°C.   
Table 5.1 Sequences and molecular weight of peptides.  
Name Sequence MW Purity 
STR-H0K3V6 Stearyl-KKKVVVVVV-NH2 1263.3 96.2% 
STR-H3K3V6 Stearyl-HHHKKKVVVVVV-NH2 1676.7 95.3% 
STR-H6K3V6 Stearyl-HHHHHHKKKVVVVVV-NH2 2088.1 92.8% 
STR-H3K6V6 Stearyl-HHHKKKKKKVVVVVV-NH2 2060.2 95.4% 
STR-H3K3V9 Stearyl-HHHKKKVVVVVVVVV-NH2 1972.1 94.3% 
STR-H3K9V6 Stearyl-HHHKKKKKKKKKVVVVVV-NH2 2444.8 96.1% 
 
 
The peptide/siRNA complexes were prepared in RNase free water for characterization 
experiments, and were prepared in Opti-MEM (Invitrogen, Carlsbad, CA, USA) for 
transfection experiments. The peptide/siRNA complexes were prepared at different molar 
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into siRNA solution with pipette. The complexes were incubated at room temperature for 30 
min before conducting experiments.   
Lipofectamine 2000, purchased from Life Technologies, was used as positive control in 
experiments. The lipo2000/siRNA complexes were prepared in Opti-MEM for transfection 
experiments, by slowly manually mixing the lipo 2000 solution into siRNA solution with 
pipette. The ratio of lipo 2000/siRNA remains unknown, since the concentration of lipo 2000 
was not revealed by the manufacturer. The amount of lipo 2000 was 1.0 µl/well for 24-well 
plate, and 0.25 µl/well for 96-well plate, according to the manufacturer’s instructions. 
5.2.2 Sequence of siRNAs 
The siRNA targeting Bcl-2 oncogene was synthesized by Sigma, with a sense sequence of 
5’-GGT GGG GTC ATG TGT GTG G-dTdT, and antisense sequence of 5’-CGG TTC AGG 
TAC TCA GTC ATC C-dTdT. The SilencerTM Cy3-labeled GAPDH siRNA was purchased 
from Life Technologies (Burlington, ON, Canada) and used in Fluorescence Activated Cell 
Sorting (FACS). Targeting glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, the 
silencer GAPDH siRNA was also purchased from Life Technologies and the sequence was 
not revealed by the manufacturer. The eGFP siRNA was synthesized by Dharmacon with an 
extinction coefficient of 362408 L/mol cm. The sense sequence of eGFP siRNA was 5’-GAC 
GUA AAC GGC CAC AAG UUC-dTdT, and antisense sequence was 5’-ACU UGU GGC 
CGU UUA CGU CGC-dTdT. The negative control siRNA with scrambled sequence used in 
the experiment was also purchased from Life Technologies. 
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5.2.3 Ribogreen assay 
The amounts of siRNA were quantified by ribogreen assay (Quanti-ITTM RiboGreen, 
Invitrogen, USA). Peptides were mixed with siRNA to form peptides/siRNA complexes as 
described above. According to manufacturer’s instruction, the complexes solution and 
ribogreen solution was prepared separately, and the aqueous working solution of ribogreen 
assay was slowly added into each sample manually. Each sample was incubated at room 
temperature for 3 min before measured on UV-Vis spectrometer (Ultrospec 4300 Pro, GE, 
Canada) with excitation at 480 nm and the emission at 520 nm.  
5.2.4 Particle size  
The hydrodynamic diameter of peptide/siRNA complexes were determined on a Zetasizer 
Nano ZS (Malvern Instruments, U.K.) equipped with a 4 mW He-Ne laser operating at 633 
nm. The complexes were prepared as described above at a molar ratio of 60/1, with a final 
siRNA concentration of 100 nM. The light intensity of complexes was collected at an angle of 
173°.  
5.2.5 Atomic force microscopy (AFM) 
The morphology of peptide/siRNA complexes was observed by AFM (Dimension Icon, 
Bruker, California, USA) at a molar ratio of 60/1. The complexes were prepared as described 
above, and were loaded on a freshly cleaved-mica surface. The samples were then washed 
twice and allowed to air-dry overnight. Standard tips (Bruker, California, USA) were used. 
Samples were visualized in peak force quantitative nanomechnics (PeakForce QNM) mode, an 
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extension of peak force tapping mode, at 1.0 Hz scanning rate. The scanned image was 
collected from a 1 x 1 µm area. 
5.2.6 Cell culture and peptide mediated siRNA transfection 
Transfection experiments were conducted on various cell lines. Human lung cancer cell 
line (A549, ATCC CCL-185) and Chinese hamster ovary cell line (CHO-K1, ATCC CCL-61) 
were maintained in F-12K medium (Thermo scientific, Ottawa, Canada) supplemented with 
10% fetal bovine serum (FBS, Sigma-Aldrich, Oakville, Ontario, Canada) at 37°C in 5% CO2. 
HeLa cells (ATCC CCL-2) were maintained in Minimum Essential Medium (Thermo 
scientific, Ottawa, Canada) supplemented with 10% FBS at 37°C in 5% CO2. Human 
pancreatic cancer cell line (Panc-1, ATCC CCL-1469) were maintained in Dulbecco’s 
Modified Eagle Medium high glucose (Thermo scientific, Ottawa, Canada) supplemented with 
10% FBS at 37°C in 5% CO2.  
Before transfection, A549 cells were seeded in 24-well plates with a confluence of 40,000 
cells/well or 60,000 cells/well, and in 12-well plates with a confluence of 100,000 cells/well. 
CHO-K1 cells were seeded in 24-well plates with a confluence of 35,000 cells/well or 60,000 
cells/well, and in 96-well plates with a confluence of 6,000 cells/well. HeLa cells were seeded 
in 24-well plates with a confluence of 40,000 cells/well, and Panc-1 cells were seeded in 24-
well plates with a confluence of 45,000 cells/well.  
After incubating at 37°C for 24 hours, cells were rinsed with phosphate buffered saline 
(PBS), and then replaced with Opti-MEM. The peptide/siRNA complexes were prepared as 
described above, diluted in Opti-MEM to a final concentration of 50 nM siRNA and then 
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added to each well. After incubated at 37°C for 4 hours, the cells were proceeded to collection 
for flow cytometry, or supplemented with medium containing FBS to obtain a final 
concentration of 10% FBS. 
The C166-GFP cells (ATCC: CRL-2583) were cultured in Dulbecco’s Modified Eagle 
Medium high glucose containing 10% FBS at 37°C in 5% CO2. The GFP cells were seeded in 
24-well plates at 40,000 cells/well and incubated for 24 hours before transfection. The cells 
were rinsed with PBS, and Opti-MEM was then added. The peptide/siRNA complexes were 
prepared as described above and were added to each well at a final concentration of 50 nM 
siRNA. To maintain cell growth, FBS was added after 4 hours of incubation to achieve a final 
concentration of 10%. 
Macrophage cells (RAW 264.7, ATCC TIB-71) were maintained in Dulbecco’s Modified 
Eagle Medium high glucose supplemented with 10% fetal bovine serum at 37°C in 5% CO2. 
Before transfection, RAW 264.7 cells were seeded in 12-well plates with a confluence of 
250,000 cells/well. After incubating at 37°C for 24 hours, cells were rinsed with PBS and 
Opti-MEM was then added. The peptide/siRNA complexes were prepared as described above, 
diluted in Opti-MEM to a final concentration of 50 nM siRNA and then added to each well. 
After the cells were incubated at 37°C for 6 hours, cells were harvested and total RNA were 
isolated. 
5.2.7 Cell viability assay 
The cytotoxicity of peptide/siRNA complexes was evaluated using 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, purchased from 
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Sigma-Aldrich. CHO-K1 ells were seeded in 96-well plates and transfected with 
peptide/siRNA complexes, as described above. After 48 hours, cells were rinsed with PBS, 
and 100 µL of MTT solution (5 mg/mL in PBS) was added to each well. After 2 hours of 
incubation at 37°C, 100 µL of solubilization solution, composed of 10% Triton X-100 (Sigma) 
plus 1% HCl (Sigma) in anhydrous isopropanol (Invitrogen), was added to each well to 
dissolve the formazan crystals. The optical densities were then measured at 570 nm with a 
microplate reader (FLUOstar Optima, BMG Labtech, Ortenberg, Germany). Cell viability was 
calculated as the optical density of each sample divided by the optical density of untreated 
controls. All measurements were performed in triplicate. 
5.2.8 Fluorescent activated cell sorting (FACS) 
The cellular uptake efficiency of complexes was quantified by flow cytometry (type BD 
Biosciences, BD FACS Vantage SE Cell Sorter, USA). CHO-K1 cells were seeded in 24-well 
plates at 60,000 cells/well, and transfected with peptide/Cy-3-labeled siRNA complexes 24 
hours later, as described above. After 4 hours of incubation at 37°C, cells were rinsed with 
PBS and incubated in 15 U/ml heparin medium for 20 min. This step was repeated 3 times. 
Cells were then washed twice with PBS, detached from the plate with 0.25% trypsin/EDTA, 
and then collected in the suspension of 4% PFA in PBS. The collected samples were analyzed 
by fluorescence acquired cell sorting (FACS), and the data were analyzed by Flowjo software. 
All measurements were performed in triplicate. 
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5.2.9 Gene silencing assay at mRNA level 
The efficiency of siRNA interference was evaluated using real time RT-PCR that shows 
the gene knockdown on mRNA level. Cells were seeded in 24-well plates and transfected with 
peptide/siRNA complexes 24 hours later, as described above. After 48 hours, total RNA was 
isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and the RNA concentration 
was measured using Nanodrop (Nanodrop spectrophotometer ND-1000, Thermo scientific, 
Ottawa, Canada). RNA was then reverse transcribed into cDNA using Bio-Rad iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Ontario, Canada). RT-PCR was performed using the 
Mx3005P™ Real Time PCR System (Agilent Technologies, Wilmington, DE, USA) with 
Brilliant II Fast SYBR Green QPCR Master Mix (Agilent Technologies), according to the 
manufacturer’s instructions. GAPDH primers used in this experiment are: 5’-TGT GTC CGT 
CGT GGA TCT GA-3’ (F), and 5’-TTG CTG TTG AAG TCG CAG GAG-3’ (R). Bcl-2 
primers used in this experiment are: 5’-GGT GGG GTC ATG TGT GTG G-3’ (F), and 5’-
CGG TTC AGG TAC TCA GTC ATC C-3’ (R). The data was normalized to cyclophilin 
genes, with primer sequences as: 5’-GGTGATCTTTGGTCTCTTCGG-3’ (F), and 5’-
TAGATGCTCTTTCCTCCTGTG-3’ (R). All measurements were performed in triplicate. 
5.2.10 Western blot 
Western blot assay were used to analyze Bcl-2 protein expression. A549 cells were seeded 
in 6-well plate with density of 10,000 cells/well, and treated after 24 hours incubation as 
described before. Cells were harvested 72 hours after treatment and samples were separated by 
12% SDS-PAGE gels and then transferred to nitrocellulose (NC) membranes. After blocking 
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with blocking buffer for 2 hours, the membranes were incubated with polyclonal rabbit anti-
Bcl-2 (Santa Cruz, California, USA) with a ratio of 1:1000 overnight at 4 °C. Horseradish 
peroxidase (HRP) conjugated goat anti-rabbit IgG was used as a secondary antibody with a 
ratio of 1:2000 for 2 hours. The bound secondary antibody was detected by enhanced 
chemiluminescence (Pierce Biotechnology, Rockford, IL, USA). β-actin was used as an 
internal standard. The images were quantified with Image J software. 
5.2.11 eGFP silencing assay 
C166 GFP cells were seeded in 24-well plates and transfected with peptide/siRNA 
targeting GFP protein complexes 24 hours later, as described above. After 48 hours of 
incubation, the cells were rinsed with PBS and collected in 4% PFA solutions. The samples 
were evaluated by FACS, and the results were analyzed by Flowjo software. 
5.2.12 In vitro complement activation assay 
The ELISA-based method for quantification of serum S-protein bound C terminal complex 
(SC5b-9) was performed. Peptides and control compound Zymosan (Sigma, Oakville, ON, 
Canada) were incubated with human serum (Quidel, San Diego, CA, USA) for 1 hour at 37 
°C. The serum was then diluted 150-fold by specimen diluent (provided in the ELISA kits). 
The SC5b-9 levels of samples were evaluated with MicroVue SC5b-9 plus kit (Quidel, San 
Diego, CA, USA) according to the manufacturer’s instruction. All measurments were 
performed in duplicate. 
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5.2.13 Cytokine activation assay 
RAW 264.7 cells were seeded in 12-well plate and transfected as described above. 6 hours 
after transfection, total RNA was isolated as described above. RT-PCR was performed with 
different primers, shown in Table 5.2. All measurements were performed in duplicate. 
 
Table 5.2 Sequences of primers for RT-PCR with cytokine activation assay 
Gene Sequences of primer 
β-actin F: AGAGGGAAATCGTGCGTGAC 
 
R: CAATAGTGATGACCTGGCCGT 
iNOS F: CAGCTGGGCTGTACAAACCTT 
 
R: CATTGGAAGTGAAGCGTTTCG 
COX-2 F: AGAAGGAAATGGCTGCAGAA 
 
R: CTCAATACTGGAAGCCGAGC 
IL1-β F: CCCAAGCAATACCCAAAGAA 
 
R: GCTTGTGCTCTGCTTGTGAG 
TNF-α F: AGACCCTCACACTCAGATCATCTTC 
 
R: TTGCTACGACGTGGGCTACA 
IL6 F: AAGTGCATCATCGTTGTTCAT 
 
R: GAGGATACCACTCCCAACAGA 
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5.3 Results and Discussion 
5.3.1 Incorporation of stearic acid and valine group with positively charged lysine 
group 
The STR-KV family peptides were designed with a stearic acid moeity, a positive lysine 
amino acid block, and a hydrophobic valine block. In addition, a selected number of histidine 
residues were also included in the peptide sequences. It has been reported that the stearylation 
of cell-penetrating peptides could increase the transfection efficiency of plasmid DNAs or 
siRNAs [254-256] because stearic acid had a high affinity to cellular membranes [254]. It has 
also been demonstrated in our previous work that the addition of stearic acid helps the 
formation of complexes [269, 270].  
To co-assemble with siRNA molecules via electrostatic interactions, positively charged 
lysine residues were adopted in the peptide sequences. The number of lysine residues was 
limited to avoid cytotoxicity and immunogenicity caused by high positive charge density [271, 
272]. The structure of two hydrophobic blocks that are present in the ends of peptides has 
been employed in lipid-based gene delivery for a long time. Lipids that consisted of two 
hydrophobic tails were considered to have a lower critical aggregation concentration than 
those with a single chain : thus, they could reduce the amounts of nanoparticles that are 
needed. To adopt these advantages while reducing the cytotoxicity and avoiding possible 
immune responses, a hydrophobic valine block was incorporated in the STR-KV family of 
peptides. Histidine was employed as a linker group.  Moreover, the pH-sensitive histidine 
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residues were always employed in peptide or polymer designs to provide protonable groups 
[274].  
Based on the above designing principles, a library of six peptides was designed and 
studied to investigate the role of: 1) the positively charged lysine group, 2) the hydrophobic 
valine groups, and 3) the number of protonable hisitidine residues on the peptide-mediated 
siRNA gene silencing efficiency. 
 
5.3.2 Interaction of peptides with siRNAs and the size distribution of complexes 
To study the peptides from the STR-KV family that formed stable complexes with siRNA, 
a Ribogreen RNA intercalation assay was performed to quantitatively characterize the 
interactions between the peptides and siRNAs (Figure 5.1). The highly sensitive fluorescent 
reagent was designed to bind to free RNA, with an excitation of approximately 500 nm and an 
emission of approximately 525 nm [275]. As shown in Figure 5.1, the Ribogreen fluorescence 
intensities gradually decreased with the increasing amounts of peptides. At a pH of 7, the 
positively charged lysine residues interacted with siRNA molecules through electrostatic 
interactions. Considering 21 pairs of negatively charged nucleotides in one siRNA molecule, 
peptides with three lysine residues should at least theoretically, completely condense siRNA at 
a molar ratio of 14/1. In addition, peptide STR-H3K6V6 and STR-H3K9V6 can have a 
stronger binding affinity with siRNA molecules because there are more positively charged 
lysine amino acids in one peptide molecule: thus, there should be a sufficient charge to 
encapsulate siRNA at the lower molar ratio of 7/1 and 5/1. In Figure 5.1, the percentage of 
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free siRNAs decreased to less than 10% when the molar ratio was above 20/1 for all six 
peptides.  
 
Figure 5.1 siRNA binding capacity with peptides, measured by RiboGreen assay. siRNA 
concentration was 50 nM, and formed complexes with molar ratios ranged from 0 to 80/1. 
 
The size distributions of the peptide/siRNA complexes were examined by dynamic light 
scattering at various molar ratios. As shown in Table 5.3, the average diameter of the 
complexes ranged from 80 nm to 170 nm. Ideally, the nanoparticles with sizes below 200 nm 
was considered to be as the optimal size for the cellular internalization of nanoparticles [276]. 
Particles that were larger than 200 nm would be recognized and removed by phagocytic cells 
in vivo. Meanwhile, it worth noticed that the size distribution of STR-H3K3V9/siRNA 
complexes was wide with PDI larger than 0.5, while other peptides formed complexes 
uniformly at molar ratios larger than 20/1 with PDI ranges from 0.1 to 0.3.  
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Table 5.3 Particle sizes of peptides with siRNA complexes at different molar ratios 
Name 
MR20 
(nm) 
PDI 
MR40 
(nm) 
PDI 
MR60 
(nm) 
PDI 
MR80 
(nm) 
PDI 
STR-H0K3V6 151 > 0.5 144 0.38±0.09 129 0.33±0.05 134 0.29±0.07 
STR-H3K3V6 174 > 0.5 167 0.35±0.11 107 0.22±0.17 131 0.21±0.03 
STR-H3K6V6 147 0.31±0.17 129 0.31±0.06 101 0.27±0.02 97 0.23±0.04 
STR-H6K3V6 132 0.24±0.04 115 0.29±0.05 88 0.18±0.01 64 0.12±0.03 
STR-H3K3V9 162 > 0.5 168 > 0.5 170 > 0.5 152 > 0.5 
STR-H3K9V6 124 0.29±0.03 109 0.22±0.03 76 0.17±0.05 47 0.19±0.02 
 
 
 
5.3.3 In vitro effects of peptide/siRNA complexes on different cell lines 
To evaluate the siRNA delivery efficacy by STR-KV peptides, quantitative RT-PCR was 
utilized to measure the mRNA levels in various cell lines. Scrambled siRNA was adopted as a 
negative control and the most commonly used siRNA transfection reagent, lipofectamine 2000, 
was adopted as a positive control in the following experiments. To optimize the transfection 
conditions and determine the potency of the STR-KV family peptides, the siRNA targeting 
GAPDH gene was utilized in CHO-K1 cells (Figure 5.2A).  A total of six peptides were 
complexed with siRNA at four molar ratios, i.e., the molar ratios of 20/1, 40/1, 60/1 and 80/1. 
The expression of GAPDH mRNA percentage mediated by lipo2000/siRNA was 19.2%±3.2%, 
and the STR-KV peptides with siRNA complexes showed different extents of silencing 
efficacy. When compared at the optimal molar ratios of STR-KV peptides, STR-
H3K3V6/siRNA induced the highest silencing effect with mRNA expression percentages of 
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25.4%±8.1% at a molar ratio of 60/1, and STR-H3K9V6/siRNA reduced the mRNA 
expression level to a lesser extent, i.e., 42.7%±4.2% at a molar ratio of 40/1, whereas others 
showed mRNA levels higher than 65%.  
To further confirm the gene silencing efficiency, STR-H3K3V6/siRNA complexes were 
transfected in A549 cells with Bcl-2 genes at various molar ratios. As shown in Figure 5.2B, 
the scrambled siRNA could not reduce the Bcl-2 mRNA levels in the cells, regardless of 
whether they were complexed with lipo2000 or peptides. In contrast, the mRNA reduction 
percentage of the STR-H3K3V6/siRNA complexes at a molar ratio of 60/1 was, at most, 
19.7%±5.9%, which was comparable to the lipo2000/siRNA results, i.e., 14.9%±3.5%. 
Interestingly, the knockdown efficiency that was induced by STR-H3K3V6/siRNA decreased 
when increasing the number of complexes during transfection, i.e., the Bcl-2 mRNA level was 
39.2%±4.3% at a molar ratio of 80/1. The transfection results for HeLa and Panc-1 cells 
demonstrated the same trend (Figure 5.2C and 2D respectively), which showed a similarly 
highest silencing efficiency at a molar ratio of 60/1, i.e., 18.6%±5.7% and 20.2%±6.8% 
respectively, and then decreased at MR80.  
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Figure 5.2 Inhibition of GAPDH or Bcl-2 activity on mRNA level through real time RT-
PCR, with siRNA conc. = 50 nM/well. Peptide/scrambled siRNA complexes were used as 
negative control in each group. Lipofectamine 2000 was used as a positive control. Percentage 
of targeting gene knockdown efficiency calculated as: (1 – (peptide/siRNA targeting gene 
expression) / (peptide/scrambled siRNA expression)) x 100%. The experiments are carried on 
CHO-K1 cells with GAPDH siRNA (A), A549 cells with Bcl-2 siRNA (B), HeLa cells with 
Bcl-2 siRNA (C), and Panc-1 cells with Bcl-2 siRNA (D).  
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The results obtained with the STR-KV peptides demonstrated that the gene-silencing 
efficiency not only was linked to the amount of positively charged residues but was also 
affected by the number of histidine groups, e.g., STR-H3K3V6 and STR-H6K3V6 had the 
same number of lysine residues, but the efficiencies varied. There was the same number of 
histidine groups and positively charged lysines in STR-H3K3V6 and STR-H3K3V9, but STR-
H3K3V6/siRNA complexes achieved much better knockdown efficiency than STR-
H3K3V9/siRNA, which suggested that the combination of histidine, lysine and valine might 
also be essential to a high transfection efficiency. Based on DLS results in Table 5.3, the 
average size of STR-H3K3V9/siRNA complexes was larger than the one of STR-H3K3V6, 
which might suggest the increase of valine residues result in morphology changes of 
complexes. Visualized by atomic force microscopy (AFM), the results were consistent with 
DLS results. As shown in Figure 5.3A, the diameter of the main particles of STR-
H3K3V6/siRNA in AFM imaging was approximately 100 nm, with a typical morphology of 
round shape. However, aggregation of complexes was observed in AFM images of STR-
H3K3V9/siRNA (Figure 5.3B), which led to difficulty to observe the actual morphologies of 
STR-H3K3V9/siRNA complexes. These results suggested a possible explanation of low 
silencing efficiency of STR-H3K3V9/siRNA: the addition of valine resulted in aggregation of 
complexes that was not favor for cellular transfection. The increased size would affect the 
functionality of the nanoparticles in various aspects, e.g., the cellular internalization pathway 
might vary , the cellular uptake efficiency might decrease when the size increases [278, 279], 
and the siRNA encapsulation ability and release from nanoparticles might vary [280]. 
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Figure 5.3 Morphology investigation of peptide/siRNA complexes. A: A typical AFM 
image of STR-H3K3V6/siRNA complexes at MR 60, with a 1 µm x 1 µm scan.  B: A typical 
AFM image of STR-H3K3V9/siRNA complexes at MR 60, with a 1 µm x 1 µm scan 
 
The siRNA delivery efficiency by STR-KV peptides was investigated at the protein level 
with KDalertTM GAPDH assay kit. As shown in Figure 5.4A, the GAPDH protein activity 
reduction profile was in accordance with the previous gene-silencing results observed at the 
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mRNA level. STR-H3K3V6/siRNA and STR-H3K9V6/siRNA showed GAPDH protein 
silencing efficiency as 63%±27% and 49%±12% respectively. The results were further 
confirmed with employing STR-H3K3V6 peptide with eGFP siRNA on C166-GFP cells 
(Figure 5.4B). Again, STR-H3K3V6/siRNA showed highest knockdown efficiency at a molar 
ratio of 60/1. No suppression of GAPDH protein was observed with peptide/scrambled siRNA 
treated cells, whereas STR-H3K3V6/siRNA (MR60) inhibited GFP protein to 41%±3.9%, a 
lesser extent than lipo2000/siRNA complexes, i.e., 49%±4.4%.  
The protein reduction activity was further analyzed on A549 cells that were transfected 
with peptide/Bcl-2 siRNA complexes by the western blotting technique. β-actin was adopted 
as an internal control in this experiment. As shown in Figure 5.4C, the naked Bcl-2 siRNA 
without peptides and the scrambled siRNA with STR-H3K3V6 complexes did not change the 
Bcl-2 protein level. In contrast, STR-H3K3V6/siRNA at the molar ratio of 60/1 significantly 
reduced the level of Bcl-2 protein. These results suggest that the peptide STR-H3K3V6 is an 
effective siRNA delivery reagent at both the mRNA level and protein level on various cell 
lines. 
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Figure 5.4 Inhibition of GAPDH, eGFP, or Bcl-2 activity on protein level, with siRNA 
conc. = 50 nM/well. The experiments were carried out on CHO-K1 cells evaluating GAPDH 
protein activity with GAPDH KDalert kit assay (A), C166-GFP cells evaluating GFP protein 
activity with flow cytometry (B), and A549 cells evaluating Bcl-2 protein activity with 
Western Blotting assay (C). 
 
 
To determine the cellular uptake efficiency of the complexes, fluorescence-activated cell 
sorting (FACS) was adopted to measure the fluorescence intensity of the cells that were 
treated with carrier/Cy-3 labeled siRNA. Before analyzing the results by FACS, the cells were 
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washed with 15 U/ml heparin in Opti-MEM three times at 37°C [147] to eliminate the effect 
of the complexes that were attached to the surfaces of the cells [261]. As expected, the 
uncomplexed siRNA could not be delivered into the cells, whereas the uptake efficiency was 
significantly improved when the siRNA formed complexes with peptides (Figure 5.5). The 
FACS results were in accordance with the gene silencing results shown previously (Figure 5.2 
and 5.4); the STR-H3K3V6/Cy-3 siRNA exhibited the highest uptake efficiency at the molar 
ratio of 60/1, while both STR-H3K3V9/Cy-3 siRNA and STR-H3K6V6/Cy-3 siRNA 
complexes showed large amounts of uptake at the molar ratio of 40/1. Although 
lipo2000/siRNA demonstrated an excellent gene-silencing ability, the cellular uptake 
efficiency of the complexes was relatively lower than STR-H3K3V6, or comparably with 
STR-H3K3V9 and STR-H3K6V6.   
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Figure 5.5 Uptake efficiency of peptide/siRNA complexes on CHO-K1 cells with siRNA 
conc. = 50 nM/well. The fluorescence intensity of internalized complexes measured by FACS, 
analyzed by flowjo in the Cy-3 channel.  
 
5.3.4 In vitro cell viability and complement activation assay 
A good gene delivery system should be safe, and should not induce cytotoxicity or 
stimulate the immune system. To investigate the cell viability of the peptide/siRNA 
complexes, an MTT assay was conducted on CHO-K1 cells. As shown in Figure 5.6A, a less 
than 10% cell death was detected for most peptide/siRNA complexes. Under transfection 
conditions, i.e., a molar ratio of 60/1, STR-H3K9V6/siRNA induced an approximately 20% 
cell death, which was higher than any other peptide/siRNA complexes but still lower than the 
lipo2000/siRNA complexes, which had with a 30% of cell death. A possible explanation was 
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the higher number of lysine groups that were present in STR-H3K9V6. It has been reported 
that highly positively charged nanoparticles might induce cytotoxicity because the positively 
charged residues would interact with the cell membranes and cause aggregation or rupture of 
the membrane surfaces [262]. 
To investigate the immune recognition of the peptide/siRNA complexes in involving the 
proinflammatory cytokines, the mRNA levels of various cytokines were evaluated by 
quantitative RT-PCR. Macrophages RAW 264.7 cells were adopted in this experiment 
because macrophages first interact with external particles in the bloodstream with respect to 
the immune system [281], and they are one of the most common cells that are involved in 
innate and adaptive immune systems. Bacterial endotoxin LPS at a concentration of 0.1 µg/mL 
were used as a positive control. As shown in Figure 5.6B, the expression of TNF-α induced by 
LPS was 6 times higher than in non-treated cells, whereas other cytokines induced by LPS 
were more than 50 times higher. In contrast, no significant cytokine expression was induced 
by the treatment of STR-H3K3V6/siRNA complexes. 
The complement activation assay was then evaluated the safety of the system, and high 
levels of complement activation was demonstrated related to a variety of diseases. The 
complement system defends the human body for the foreign objects invasion, which can be 
activated through various pathways, i.e., classical, lectin, and alternative pathways. After 
activation, the complement system will generate terminal complement complexes, i.e., TCC 
and SC5b-9 by the assembly of C5 to C9. The ELISA assay was adopted to measure the 
concentration of Sprotein-bound C terminal complex (SC5b-9) in serum. As shown in Figure 
5.6C, STR-H3K3V6 did not exhibit SC5b-9 activation, compared with positive control 
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Zymosan and negative control serum alone. Thus, the STR-H3K3V6 based siRNA delivery 
system was biocompatible without causing cytotoxicity, or showing any complement or 
cytokines stimulations.    
 
Figure 5.6 In vitro toxicity and biocompatibility of peptide/siRNA complexes, with siRNA 
conc. = 50 nM/well. A: Cell viability of peptide/siRNA complexes were performed on CHO-
K1 cells with MTT assay. B: Cytokine mRNA expression of peptide/siRNA complexes were 
performed on RAW 264.7 cells, 0.1 µg/mL LPS was adopted as positive control. C: SC5b-9 
formation in human serum was quantified by ELISA kit assay, 5 µg/mL Zymosan was adopted 
as positive control. 
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5.4 Conclusions 
In this chapter, a series of peptides was designed and investigated for their use as potential 
siRNA delivery systems. Various numbers of lysine and valine residues were selected and 
combined with histidine residues and stearic acid in an effort to improve siRNA delivery and 
cell viability. The results revealed that the peptide STR-H3K3V6, a new cell-penetrating 
peptide that consists of a stearic acid moiety with a sequence of STR-HHHKKKVVVVVV, 
could efficiently facilitate siRNA delivery. The peptide STR-H3K3V6 efficiently 
encapsulated siRNAs from molar ratio 20/1, and the formed complexes were around 100 nm 
in diameter, which was suitable for nanoparticle devliery. The STR-H3K3V6/siRNA 
complexes induced 80%-90% gene-silencing efficiency at mRNA level on four cell lines. In 
addition, this peptide-based delivery system is safe and biocompatible, as no obvious 
cytotoxicity or immune responses observed in vitro, in terms of complement or cytokine 
activation assay. Our data suggested that peptide STR-H3K3V6 improved siRNA delivery on 
various cell lines with low cytotoxicity, and can be used as delivery carriers for siRNA 
therapeutics.  
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Chapter 6 
Investigation of uptake mechanisms and direct translocation 
properties of a new CPP for siRNA delivery 
 
 
6.1 Introduction 
Since their discovery, the CPP uptake mechanism has been extensively studied, and 
several hypotheses have been proposed [137, 282-284]. No universal uptake pathway can be 
applied to all CPPs, and the internalization route can be affected by various factors, including 
the CPP concentration and structure, the physical properties of cell membranes, the interaction 
between CPPs and cell membranes, and the nanoparticles carried by CPPs.  
Direct penetration and endocytosis have been suggested as the two main uptake 
mechanisms. CPPs that can enter cells at a low temperature are considered internalized via a 
direct translocation pathway [285]. However, several studies report that increasing the 
concentration of CPPs might trigger direct penetration [139, 286, 287]. Tat and penetratin 
have both been internalized through endocytosis under most conditions, but they were also 
taken up via direct translocation at high concentrations [137, 139, 146]. However, several 
studies show that triggering direct penetrating by increasing the CPP concentration might lead 
to high cytotoxicity of nanoparticles due to biological membrane damage [146, 288]. 
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Endocytosis is the other common mechanism for nanoparticle internalization, including 
clathrin-dependent endocytosis, macropinocytosis and caveolae-dependent endocytosis. In 
uptake through an endocytic pathway, CPPs first interact with extracellular components via 
electrostatic interactions, such as heparin sulfate proteoglycans and chondroitin sulfate 
proteoglycans [289, 290]. These anionic proteoglycans are abundant on the cellular membrane 
surface and are receptors for nanoparticle internalization [289, 290]. However, the 
nanoparticles internalized through endocytosis pathways may be trapped in endosomes and 
then degraded in late lysosomes, which reduces the biological potency of these nanoparticles. 
Moreover, evidence shows that direct translocation and endocytosis can coexist for the same 
CPP [291, 292]. Despite differences in their mechanisms, direct translocation and endocytosis 
might initiate the internalization process through interactions with the same components at 
cellular membranes [293]. For instance, heparan sulfate proteoglycans on the cell membrane 
surface are involved in both endocytosis and direct penetration of CPPs [294]. 
To facilitate siRNA cellular uptake and gene silencing efficiency, we previously 
developed a cell-penetrating peptide for siRNA delivery in the form of STR-H3K3V6/siRNA 
complexes (abbreviated to STR-KV/siRNA in this chapter). With the sequence STR-
HHHKKKVVVVVV, the peptide STR-KV has shown 90% gene knockdown efficiency in 
various cell lines with limited cytotoxicity, discussed in Chapter 5. To further improve our 
delivery system for in vivo applications, a comprehensive study on the cellular uptake 
mechanism and intracellular trafficking of STR-KV/siRNA complexes is necessary.  
Herein, we investigated the cellular internalization mechanism for STR-KV/siRNA 
complexes using different biochemical probes/methods. Several endocytosis inhibitors were 
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used to block certain pathways, and the impact of temperature and the mitochondrial process 
inhibitor were also evaluated in detail. Moreover, the interaction between the complexes and 
cell membrane components was investigated. Confocal microscopy was also used to study co-
localization of the delivery system with endosome/lysosome compartments and intracellular 
trafficking of the STR-KV/siRNA complexes. 
This Chapter is based on the work submitted to Molecular Pharmaceutics, with authorship 
as: Ran Pan, Wen Xu, Yong Ding, Sheng Lu, Lei Zhang, Pu Chen. 
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6.2 Materials and methods 
6.2.1 Formulation of peptide/siRNA complexes  
Synthesized by CanPeptide Inc (Quebec, Canada), peptides were dissolved in RNase free 
water (Thermo scientific, Ottawa, Canada) at a concentration of 1 mM, followed by probe 
sonication for 10 min, and were stored at -20°C. Synthesized by Sigma-Aldrich (Oakville, 
Ontario, Canada) or Life Technologies (Burlington, Ontario, Canada), siRNAs were dissolved 
in RNase free water at a concentration of 50 µM, and were store at -80°C.   
The peptide/siRNA complexes were prepared in RNase free water for characterization 
experiments, and were prepared in Opti-MEM (Invitrogen, Carlsbad, CA, USA) for 
transfection experiments. The peptide/siRNA complexes were prepared at different molar 
ratios depending on the designed experiment, by slowly manually mixing the peptide solution 
into siRNA solution with pipette. The complexes were incubated at room temperature for 30 
min before conducting experiments.   
6.2.2 Sequence of siRNAs 
The SilencerTM Cy3-labeled GAPDH siRNA with excitation/emission as 547/563 nm was 
purchased from Life Technologies, used in Confocal Laser Scanning Microscopy (CLSM) and 
Fluorescence Activated Cell Sorting (FACS). The MISSIONTM Cy-5 labeled Negative Control 
#1 siRNA with excitation/emission as 650/670 nm was purchased from Sigma-Aldrich, used 
in Confocal Laser Scanning Microscopy. Silencer GAPDH siRNA, targeting glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) gene, was purchased from Life Technologies and the 
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sequence was not revealed by the manufacturer. The negative control siRNA with scrambled 
sequence used in the experiment was also purchased from Life Technologies. 
6.3 RiboGreen assay 
The amounts of free siRNA were quantified by RiboGreen assay (Quanti-ITTM RiboGreen, 
Invitrogen, USA). Peptides were mixed with siRNA to form peptides/siRNA complexes as 
described above. Different concentrations of heparin were added to the complexes and 
incubated for 1 hour before conducting RiboGreen assay. According to manufacturer’s 
instruction, the complexes solution and ribogreen solution was prepared separately, and the 
aqueous working solution of ribogreen assay was slowly added into each sample manually. 
Each sample was incubated at room temperature for 3 min before measured on UV-Vis 
spectrometer (Ultrospec 4300 Pro, GE, Canada) with excitation at 480 nm and the emission at 
520 nm.  
6.3.1 Cell culture and peptide mediated siRNA transfection 
Transfection experiments were conducted on various cell lines. Human lung cancer cell 
line (A549, ATCC CCL-185) and Chinese hamster ovary cell line (CHO-K1, ATCC CCL-61) 
were maintained in F-12K medium (Thermo scientific, Ottawa, Canada) supplemented with 
10% fetal bovine serum (FBS, Sigma-Aldrich, Oakville, Ontario, Canada) at 37°C in 5% CO2. 
HeLa cells (ATCC CCL-2) were maintained in Minimum Essential Medium (Thermo 
scientific, Ottawa, Canada) supplemented with 10% FBS at 37°C in 5% CO2. Before 
transfection, A549 cells were seeded in 24-well plates with a confluence of 60,000 cells/well 
for uptake experiments, and 40,000 cells/well for knockdown experiments. CHO-K1 cells 
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were seeded in 24-well plates with a confluence of 60,000 cells/well for uptake experiments 
and 35,000 cells/well for knockdown experiments. HeLa cells were seeded in 24-well plates 
with a confluence of 50,000 cells/well for uptake experiments and 30,000 cells/well for 
knockdown experiments. 
After incubation at 37°C for 24 hours, cells were rinsed with phosphate buffered saline 
(PBS), and then replaced with Opti-MEM. The peptide/siRNA complexes were prepared as 
described above, diluted in Opti-MEM and added to each well with a final concentration of 50 
nM siRNA and 3 µM peptide. After incubated at 37°C for 4 hours, the cells were proceeded to 
collection for flow cytometry, or supplemented with medium containing FBS to obtain a final 
concentration of 10% FBS and incubated for a total of 48 hours before analyzing with RT-
PCR. 
6.3.2 Heparin competition assay 
Cells were seeded and transfected with peptide/siRNA complexes in 24 hours, as 
described above. 30 min prior to and 4 hours after transfection, 3 µg/ml of heparin containing 
medium was added to each well. The cells were incubated at 37°C for 4 hours and then 
collected for flow cytometry. 
6.3.3 GAG lyases assay 
The cells were seeded and incubated as described above. Washed with PBS, cells wer pre-
treated with 5 mIU/ml of heparinase III from Flavobacterium heparinum reconstituted in 20 
mM Tris-HCl buffer (pH 7.5 with 0.1 mg/ml BSA and 4 mM CaCl2), or with 20 mIU/ml of 
chondroitinase ABC from Proteus vulgaris in 50 mM Tris buffer (pH 8.0 with 60 mM sodium 
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acetate and 0.02% BSA) [295]. After 2 hours incubation with heparinase III or chondroitinase 
ABC, the cells were rinsed gently 6 times with PBS and then transfected with peptide/Cy-3-
labeled siRNA complexes as described above. 4 hours later, the cells were washed and 
collected to analyze with flow cytometry. 
6.3.4 Treatments of the cells with endocytic inhibitors 
The cells were seeded and incubated as described above. 1 hour before transfection, the 
medium was discarded and cells were rinsed with PBS, which was then replaced with Opti-
MEM. The freshly prepared chemical inhibitors were then added to each well and incubated 
for 1 hour. The cells were then transfected with peptide/siRNA as described above. After 4 
hours incubation at 37°C, the medium was discarded, then the cells were washed with 0.5 
mg/ml trypsin in PBS for 5 min, and 0.5 mg/ml heparin in Opti-MEM for 20 min to remove 
the complexes attached on cell membranes. This step was repeated for 3 times before 
collection for flow cytometry. 
For positive control, the cells were treated with 18 µg/ml of Transferrin for 15 min, or with 
0.75 µM of LacCer for 15 min. After 3 hours incubation, the cells were washed 3 times with 
ice-cold Opti-MEM, then incubated in ice-cold washing buffer for 2 min (0.2 M acetic acid 
with 0.2 M NaCl in PBS) to remove Transferrin, or incubated in ice-cold 5% BSA for 10 min 
for 4 times to remove LacCer. The cells were then washed with ice-cold PBS and Opti-MEM 
before collection for flow cytometry. 
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6.3.5 Effects of cellular energy state on internalization 
The temperature dependent uptake experiments were conducted both at 37°C and 4°C. The 
cells were seeded in 24-well plates as described above 24 hours before transfection. For low 
temperature experiments, cells were incubated at 4°C 1 hour prior to, and 4 hours after treated 
with peptide/Cy-3 labeled siRNA complexes. 4 hours after transfection, the cells were washed 
and collected to analyze with flow cytometry.  
Alternatively, cells were pre-treated with sodium azide (200 µM) for 30 min prior to and 4 
hours after transfected with peptide/Cy-3 labeled siRNA. 4 hours after transfection, the cells 
were washed and collected to analyze with flow cytometry.  
6.3.6 Flow cytometry  
The cellular uptake efficiency of complexes was quantified by flow cytometry (type BD 
Biosciences, BD FACS Vantage SE Cell Sorter, USA). 4 hours after transfection, cells were 
rinsed with PBS and incubated in 15 U/ml heparin containing medium for 20 min. This step 
was repeated for 3 times. Cells were then washed twice with PBS, detached from the plate 
with 0.25% trypsin/EDTA, and then collected in the suspension of 4% PFA in PBS. The 
collected samples were analyzed by fluorescence acquired cell sorting (FACS), and the data 
were analyzed by Flowjo software. All measurements were performed in triplicate. 
6.3.7 GAPDH silencing assay at mRNA level 
The efficiency of GAPDH siRNA interference was evaluated using real time RT-PCR that 
shows the gene knockdown on mRNA level. Cells were seeded in 24-well plates and 
transfected with peptide/siRNA complexes 24 hours later, as described above.  
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After 48 hours, total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, 
USA), and the RNA concentration was measured using Nanodrop (Nanodrop 
spectrophotometer ND-1000, Thermo scientific, Ottawa, Canada). RNA was then reverse 
transcribed into cDNA using Bio-Rad iScript cDNA synthesis kit (Bio-Rad Laboratories, 
Ontario, Canada). RT-PCR was performed using the Mx3005P™ Real Time PCR System 
(Agilent Technologies, Wilmington, DE, USA) with Brilliant II Fast SYBR Green QPCR 
Master Mix (Agilent Technologies), according to the manufacturer’s instructions. All 
measurements were performed in triplicate. 
6.3.8 Confocal laser scanning microscopy (CLSM)  
A549 cells were seeded in a Nunc Lab-Tek II 4-well glass chamber slides (Thermo 
scientific, Ottawa, Canada) at 60,000 cells/well, and transfected with peptide/Cy-3-labeled 
GAPDH siRNA, or peptide/Cy-5-labeled Negative Control siRNA complexes 24 hours later, 
as described above.  
For endosome/lysosome co-localization experiments, 75 nM/well of Lysotracker Green 
(Life Technology, Carlsbad, USA) were added into the medium 3 hours after transfection and 
incubated at 37 °C for 1 hour. 3 hours after transfection, cells were then incubated in 15 U/ml 
heparin containing medium for a total one hour at 37 °C, and rinsed twice with PBS. 500 µL 
of medium were added into each well, with 1 drop of NucBlue Live ReadyProbes Reagent 
(Life Technology, Carlsbad, USA). Carl Zeiss LSM 700 confocal microscope (Zeiss, Jena, 
Germany) was used to visualize the cells. The microscope was equipped with Plan-
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Apochromat 20x/0.8 NA objective lens. The images were analyzed with Olympus FluoView 
FV1000 software. 
For multi-positioned time-lapse imaging, cells were treated with peptide/Cy-5 labeled 
siRNA complexes for 10 min, and then rinsed with PBS. Fresh 500 µL of Opti-MEM were 
added into each well, and 10 µL of 1X CellMask™ Green Plasma Membrane Stain (with 
excitation/emission as 522/535 nm, purchased from Life Technologies) were added to each 
well. Before visualize the samples with Nikon A1R confocal microscope system, equipped 
with Nikon Eclipse Ti Advanced PFS for time-lapse imaging station, 1 drop of NucBlue Live 
ReadyProbes Reagent (purchased from Life Technologies) was added to each well. The 
microscope was equipped with Nikon T-P2 objective lens. The images were analyzed and 
complied into movie clips with Nikon NIS Elements Viewer software. 
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6.4 Results and Discussion   
6.4.1 Study the interactions between complexes and cell surface proteoglycans  
Whether though endocytosis or direct translocation, universally, interactions with the 
cellular membrane are first involved in the CPP internalization process [296, 297]. Most CPPs 
initiate the internalization processes through electrostatic interactions with the anionic heparan 
sulphate proteoglycans (HSPGs) located on the cell membrane [298, 299]. Studies show that 
HSPGs are essential for defining cationic nanoparticle uptake by the cells. For example, the 
level of uptake for certain peptides was reduced or inhibited in glycosaminoclycans-deficient 
cell lines [300-302], which demonstrates that the CPP uptake process depends on interaction 
between CPPs and certain HSPGs. In addition, the HSPG expression levels differ based on 
cell type, e.g., the glycosaminoclycan (GAG) HSPGs are overexpressed on most cancer cell 
membranes [303-305] and might regulate or favor uptake of certain CPPs in specific cell lines 
[304, 306, 307]. Thus, to investigate interactions with HSPGs and the role of HSPGs in STR-
KV/siRNA complex internalization, heparin interaction assays and GAG lyases assays were 
performed using CHO-K1, A549 and HeLa cells.  
As shown in Figure 6.1A, co-incubating various cells with the HSPG analogue heparin 
decreased uptake of STR-KV/siRNA complexes, which implies that the presence of heparin 
hinders transfection of STR-KV/siRNA complexes. This result also suggests that the STR-
KV/siRNA complexes interact with and bind to HSPGs. The uptake efficiency might be 
reduced for 2 reasons: 1) a heparin analogue competing with the HSPGs at the cell surface for 
binding to the STR-
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our complexes. To better understand the role of heparin in uptake of the STR-KV/siRNA 
complexes, a RiboGreen assay was used to quantify the complex dissociation percentage due 
to heparin, and a GAG lyases assay was used to investigate the influence of HSPGs on STR-
KV/siRNA complex internalization. 
The RiboGreen reagent is designed to intercalate with free siRNA and emit a strong 
fluorescence signal at 525 nm; thus, the percentage of dissociated siRNA can be detected and 
calculated based on fluorescence intensity [308]. The siRNA-Ribogreen fluorescence intensity 
is shown in Figure 6.1B. The complexes began to dissociate with 1 µg/ml of heparin and 
reached a plateau at 7.5 µg/ml of heparin, which implies complete dissociation of the 
complexes. Calculated from Figure 6.1B, ~ 15% of the complexes dissociated at the 
concentration of heparin from the previous experiment, assuming a linear relationship between 
the dissociation percentage and increased level of heparin. Thus, the presence of a heparin 
analogue caused partial dissociation of the complexes, and more than 80% of complexes 
remained intact in the previous experiment. This result implies that the decrease in complex 
uptake shown in Figure 6.1A might be mainly due to the complexes binding with exogenous 
negatively charged components. 
The negatively charged glycosaminoglycans are a group of cell surface receptors 
covalently linked to cell surface proteins, e.g., HSPGs [309] and chondroitin sulfate 
proteoglycans (CSPGs) [310]. In the following experiments, two types of GAG lyases were 
used to remove the GAGs at the cell membrane surface. Heparinase III from Flavobacterium 
heparinum was used to remove the HS glycosaminoglycans, and chondroitinase ABC from 
Proteus vulgaris was used to remove the CS glycosaminoglycans (CS-A, -B, -C) [311]. As 
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shown in Figure 6.1C, internalization of STR-KV/siRNA complexes was not affected by the 
heparinase III pretreatment, and a slight decrease was observed with the chondroitinase ABC-
treated cells. This result suggests that enzymatic removal of cell surface HSPGs and CSPGs 
does not affect the quantity of complexes taken up by the cells. In other words, the HSPG 
interactions are not essential for cellular uptake of our complexes. 
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Figure 6.1 Interactions between complexes and cell surface proteoglycans, with siRNA 
conc. = 50 nM/well. (A), Interactions between complexes and HSPGs analogue heparin on 
CHO-K1 cells, A549 cells and HeLa cells. (B), Addition of heparin on peptide/siRNA binding 
affinity; (C), Effects of removal cell surface proteoglycans on complexes uptake efficiency on 
CHO-K1 cells, A549 cells, and HeLa cells. 
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6.4.2 Explore the involvement of different endocytic pathways in the complex uptake 
To better understand the uptake mechanisms, various chemical endocytosis inhibitors 
were used to study the STR-KV/siRNA complex internalization route. Chlorpromazine was 
used to block the clathrin-mediated pathway, which inhibits formation of the endocytosis sag 
coated with clathrin [312]. EIPA (5-(N-ethyl-N-isopropyl) amiloride) was used to block 
macropinocytosis and phagocytosis by inhibiting the Na+/H+ exchanger [313]. The multiple 
inhibitor methyl-β-cyclo-dextrin (MBCD) depletes the cholesterol required for both 
macropinocytosis and caveolae-mediated endocytosis [314]. Filipin and nystatin were 
employed to inhibit caveolae-mediated pathways; the former impaired caveolae invagination 
by distorting the structure and function of cholesterol-rich caveolae membrane domains [315]. 
The latter interacts with lipid cholesterol and inhibits sag formation [316]. In addition, two 
fluorescently labeled endocytic markers were used as positive controls in experiments to 
ensure the effectiveness of inhibitors. Transferrin, which is taken up by cells exclusively 
through the clathrin-mediated pathway, was used as a marker for clathrin-mediated 
endocytosis [317], and lactosylceramide (LacCer) was used for the caveolae-mediated 
pathway [318].  
As shown in Figure 6.2, a minor decrease in transferrin and LacCer fluorescence intensity 
was observed in the presence of EIPA, while STR-KV/siRNA complex internalization 
remained unchanged, which indicates that the complexes were not internalized through 
macropinocytosis. Similar results were obtained using MBCD-treated cells with no significant 
reduction in transferrin and STR-KV/siRNA complex uptake, while the LacCer uptake 
efficiency decreased to less than 50%.  
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Inhibition of the clathrin-mediated pathway by chlorpromazine (Cpz) dramatically 
decreased transferrin internalization. However, only a slight reduction was observed for 
LacCer uptake, which suggests that Cpz successfully inhibited clathrin-mediated endocytosis 
but did not affect the caveolae-mediated pathway. With a Cpz pre-treatment, a minor 
reduction (7%-18%) in Cy-3 fluorescence intensity was observed, which indicates that a small 
fraction of the complexes were internalized through the clathrin-mediated endocytic pathway.  
Filipin and nystatin are widely used to inhibit caveolae-mediated endocytosis. As 
expected, LacCer uptake decreased to less than 30% in the filipin- or nystatin-treated cells, 
while no significant effects were observed for transferrin internalization. However, a weak 
increase (5%-12%) in siRNA uptake is shown in Figure 6.3A with nystatin pre-treatment, 
perhaps because other uptake pathways can be activated as compensation when one is 
inhibited [319]. The other possible reason for the Cy-3 fluorescence intensity increase might 
be that the presence of Nystatin enhances cell membrane permeability, which sequesters the 
cholesterol at the cell membrane surface [320]. Overall, no significant differences were 
observed for the STR-KV/siRNA complex uptake intensities in the presence of any inhibitors. 
These observations suggest that the complex internalization process does not depend on 
macropinocytosis, phagopinocytosis, clathrin-mediated or caveolae-mediated endocytosis, 
which implies uptake through direct translocation. 
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Figure 6.2 Effects of different inhibitors on complexes uptake efficiency on A549 cells. 
Transferrin, marker of clathrin-mediated endocytosis, and LacCer, marker of caveolae-
mediated endocytosis, were used as positive controls. Final Concentrations used here is EIPA 
= 20 µg/ml, MBCD = 5 mg/ml, Cpz = 5 µg/ml, Fillipin = 4 µg/ml, and Nystatin = 40 µg/ml. 
 
6.4.3 Investigate the influence of cellular energy state on complexes transfection 
efficiency 
To study the impact of the cellular energy state on uptake efficiency of STR-KV/siRNA 
complexes, low temperature (4 °C) experiments were performed, and the results were 
compared with experiments at 37 °C. As shown in Figure 6.3A, a minor decrease in 
fluorescence intensity was observed for HeLa cells at 4 °C, and Cy-3-labeled siRNA uptake 
with other cell lines was not significantly affected by lowering the cell temperature. Because 
endocytosis is commonly inhibited at 4 °C, this result suggests that our complexes are 
internalized via a non-endocytic pathway. Moreover, studies also show that direct 
translocation might also be affected when the cell energy state is lowered due to the decrease 
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in cellular membrane fluidity at low temperatures , which explains the slight reduction in 
siRNA uptake at 4 °C shown in Figure 6.3A. Thus, an alternative means to assess direct CPP 
translocation through the membranes is necessary. 
Sodium azide is a potent mitochondrial oxidative phosphorylation inhibitor that abolishes 
the ATP-dependent processes and, consequently, active uptake of nanoparticles [322]; it has 
been commonly used as an endocytosis inhibitor to investigate nanoparticle cellular uptake 
pathways [323]. The cells were treated with different concentrations of sodium azide prior to 
and after transfection with STR-KV/siRNA complexes as described in 6.3.5; the mRNA levels 
were evaluated using RT-PCR. As shown in Figure 6.3B, the GAPDH levels were equally 
reduced in the presence and absence of sodium azide for various cell lines. These data are 
consistent with previous uptake results at low temperatures; both demonstrate that transfection 
efficacy is independent of the energy state of the cells. 
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Figure 6.3 Effects of cellular energy state on complexes transfection efficiency on CHO-
K1 cells, A549 cells, and HeLa cells. (A), Cells were incubated at both 37°C and 4°C during 
transfection experiments. (B), Variable concentrations of sodium azide were added to cells 
before and after transfection experiments. 
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6.4.4 Examine the internalization process of STR-KV/siRNA complexes  
Based on the above results, STR-KV/siRNA complex internalization was not affected by 
inhibitors and independent of the cellular energy levels. Before drawing the conclusion that 
the complexes were internalized through direct translocation, live cell confocal microscopy 
was used to investigate co-localization of the complexes with endosome/lysosome vesicles.  
As shown in Figure 6.4A, the endosomes/lysosomes were labeled with Lysotracker, 
which was visualized as green signals, and the Cy-3-labeled siRNAs are shown as red signals 
and are localized close to the nucleus. The merged image, as shown in the right panel of 
Figure 6.4A, yielded a yellow fluorescent signal when siRNAs co-localized with 
endosomes/lysosomes. Most Cy-3 siRNAs did not co-localize with endosomal/lysosomal 
vesicles; the software calculated less than 20% co-localization. This result is consistent with 
the previous results, which indicate that a small quantity of STR-KV/siRNA complexes use 
endocytosis, while most do not (Figure 6.2).  
Multiple points scanning confocal microscopy was used to investigate the dynamic 
internalization process of the complexes. Image collection began 10 min after transfection and 
stopped 2 h later with an interval of 2 min. This time series captured 0.16 frames per second, 
composed from 59 images. As shown in Movie 6.4B, an in situ accumulation of Cy-5 siRNAs 
was observed around nucleus in different cells, which is evidence that the STR-KV/siRNA 
complexes entered the cells.  
Time-lapse imaging can also be used for visualization with Nikon Eclipse Ti confocal 
microscope with a Z-stack viewing options, which shows a continuous process, wherein the 
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complexes internalize into cells. As shown in Movie 6.4C, the complexes in upper right (Cy-5 
was visualized as magenta) first accumulated on the cell membranes (green), yielded a white 
fluorescence signal when complexes co-localized with cell membrane. The complexes then 
entered the cells as clustered particles, and the particles accumulated around nucleus (blue), 
where the RNAi process takes place. The same internalization process can be visualized more 
clearly in Movie 6.4E with a larger area of view, the complexes were entered the cells as 
clustered particles accumulated around nucleus with diameters at approximately 300 nm 1.5 
hours after transfection. The aggregation of complexes on cell membranes was visualized in 
Movie 6.4C, as well as in Figure 6.4A and 4D; this might explain why the STR-KV/siRNA 
complexes use a direct translocation pathway but do not cause cytotoxicity. Studies show that 
increasing the CPP concentration induces direct translocation or physical endocytosis [139, 
283, 331], such as MPG [146], PEP [332], CADY [183], and others. STR-KV/siRNA 
complex aggregation increased the local complex concentration at cell membrane; thus, direct 
penetration was favored with an overall low concentration. 
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Figure 6.4 Intracellular localization of STR-KV/siRNA complexes on A549 cells, with 
siRNA conc. = 50 nM/well. Images were visualized by confocal microscopy, and 
pseudocolored for visualization. (A), Co-localization of STR-KV/ Cy-3 siRNA complexes 
with endosome/lysosome vesicles: blue = nucleus; red = Cy-3 siRNA; green = LysoTracker 
Green. Co-localization of siRNA with the endosomal/lysosomal marker is in yellow. (D), Co-
localization of STR-KV/Cy-5 siRNA complexes with cell membranes: blue = nucleus; red = 
Cy-5 siRNA; green = cell membrane.  
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Movie 6.4 Dynamic internalization process of STR-KV/siRNA on A549 cells. (B), Image 
collection began 10 min after transfection with 0.16 frames per second, composing from 59 
images with 120s interval of each. Images were pseudocolored for visualization: blue = 
nucleus; red = Cy-5 siRNA; green = cell membrane. (C) and (E), Image collection began 10 
min after transfection with a Z-stack viewing options. Z range is 11.40 µm with Z step as 0.5 
µm each. Images were pseudocolored for visualization: blue = nucleus; magenta = Cy-5 
siRNA; green = cell membrane. Co-localization of siRNA with the cell membrane is in white.  
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6.5 Conclusion 
In this chapter, the STR-KV/siRNA uptake pathway was examined using four different 
cell lines. The results show a small fraction of complex dissociation, co-incubation of the 
complexes with the HSPG analogue heparin indicates that our complexes interact with cell 
surface HSPGs, while a GAG lyase assay suggests this interaction is not essential for complex 
internalization. Applying different endocytic inhibitors to the cells showed that endocytosis 
was not the major uptake pathway for our complexes, i.e., less than 20% of the complexes 
used the clathrin-mediated pathway. Changing the cell energy state by lowering the 
temperature or adding sodium azide exhibited no minor effects on complex uptake, which 
indicates that a direct translocation route is most likely. Furthermore, confocal microscopy 
revealed that the high local complex concentration might be the trigger for complex 
internalization through an endocytosis-independent pathway. 
  
   161 
Chapter 7 
Original Contributions and Recommendations 
 
7.1 Contributions 
This dissertation presents a thorough of study of peptides as potential siRNA carriers in 
various aspects. Several cell-penetrating, co-assembling peptides were designed or modified, 
and the possibility of using these peptides for safe and efficient delivery of siRNAs was 
evaluated both in vitro and in vivo. The following aspects are included in this thesis: (1) the 
modification of the original co-assembling, cell-penetrating peptide C6M1 by conjugating 
with diethylene glycol into peptide DM1, which improved serum stability without decreasing 
the gene-silencing efficiency (Chapter 3); (2) the design of a series of stearylated peptides 
with modified nuclear localization sequences, in which, the most promising candidate STR-
HK showed around 78% knockdown efficiency in vitro and 62% tumor inhibition rate in vivo, 
with major cytotoxicity observed at molar ratio 80/1 (Chapter 4); (3) the design of a series of 
stearylated peptides, which showed improved cell viability and biocompatibility achieving 80% 
- 90% gene-silencing efficiency by peptide STR-H3K3V6/siRNA complexes in various cell 
lines (Chapter 5); (4) the exploration of the internalization pathway of peptide STR-H3K3V6 
in the previous chapter, and its uptake mechanisms, which provided information for future 
design of peptide-based delivery vehicles for siRNA (Chapter 6). The original contributions to 
research are summarized in the following sections. 
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Conjugation of diethylene glycol to a CPP to improve its serum stability:  
The development of a library of peptide-based siRNA carriers was previously reported by 
our group, which induced gene knockdown without inducing cellular toxicity. However, a 
major limitation of these carriers was that the transfection efficacy was reduced by the 
presence of serum, resulting in reduced gene knockdown efficiency. To improve the serum 
stability of the cargo while not decrease the gene-silencing efficacy, one of the most 
promising peptides C6M1 was conjugated with diethylene glycol. It was demonstrated that the 
incorporated/co-assembled siRNA complexes increased its stability in serum from less than 24 
hours to up to 72 hours, with highly efficient cellular uptake and more than 90% cell viability 
profile. In addition, the gene-silencing ability of diethylene glycol conjugated-peptide/siRNA 
complexes was comparable to that of non-conjugated peptide/siRNA at both mRNA and 
protein levels.  
 
Peptide STR-HK family as siRNA delivery carriers in vitro and in vivo:  
A series of co-assembling, cell-penetrating peptides was designed, including a variant of a 
nuclear localization sequence, i.e. PKPKRKV, 0-6 histidine residues and an optional stearic 
acid group. Among the candidates, the most promising one was STR-HK with sequence as 
STR-HHHPKPKRKV. Stearic acid was adopted as hydrophobic moiety, which improved the 
uptake efficacy of peptide. The variant of nuclear localization sequence limited nuclear 
translocation and enhanced the release of cargo into cytoplasm. The incorporation of histidine 
was aimed to improve the capability of endosomal membrane disruption, which resulted in a 
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better endosmal escape ability. The STR-HK/siRNA coassembly showed a size distribution 
ranged from 50 nm to 180 nm, confirmed by dynamic light scattering and atomic force 
microscopy. The secondary structure of STR-KV was examined by FTIR, showing a 
combination of β-sheet and β-turn structures. The gene-silencing efficiency induced by STR-
HK/siRNA complexes on A549 cells was confirmed by RT-PCR on mRNA level with the 
highest silencing effect of 78% at a molar ratio of 40/1. The CLSM images suggested that 
STR-HK/siRNA complexes were internalized within 3 hours through an endocytic pathway, 
and endosomal escape of siRNAs happened within 12 hours after treatment. Furthermore, the 
therapeutic potential of STR-HK mediated siRNA delivery was examined in vivo for cancer 
treatment by targeting Bcl-2 gene in a mouse tumor model, and demonstrated that tumor 
growth was inhibited by 62%, as a result of the downregulation of Bcl-2 protein.   
 
Peptide STR-KV famility with improved cell viability and gene-silencing efficiency and 
its internalization mechanisms:  
The STR-KV family peptides were designed with a stearic acid block, a positive lysine 
amino acids block, and a hydrophobic valine block. Positively charged lysine residues were 
adopted in the sequences in order to co-assemble with siRNA molecules via electrostatic 
interactions. Stearic acid was introduced to improve the cellular uptake of complexes. The pH-
sensitive histidine residues were employed in the designs to provide protonable groups. Valine 
groups were added to improve the interactions with cell membrane while reduce the possible 
cytotoxicity and immunogenicity. The number of lysine, histidine and valine amino acids was 
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carefully examined on its binding affinity with siRNA molecules, and its gene-silencing 
efficacy induced by the corresponding peptide/siRNA complexes on a range of cell lines. 
Within the newly designed peptide family, the most pronounced gene silencing could be 
achieved with the peptide STR-H3K3V6, which showed a high knockdown efficiency (80% - 
90% on various cell lines) rarely reported before. No obvious cytotoxicity was observed with 
peptide or peptide/siRNA complexes on the four cell lines we chose. The biocompatibility of 
the peptide STR-H3K3V6 was evaluated in terms of complement activation and cytokine 
activation, and no obvious responses were observed in vitro.  
Understanding the uptake mechanisms of cell-penetrating peptide-based siRNA delivery 
systems will facilitate the development of safe and efficient gene delivery vectors. Thus, the 
internalization process and intracellular trafficking of the STR-H3K3V6/siRNA (in short as 
STR-KV/siRNA) complexes was explored. It was confirmed that the electrostatic interaction 
of peptide/siRNA complexes with heparan sulphate proteoglycans (HSPGs) at the cell surface 
was essential to triggering the uptake process. In addition, conducting uptake experiments at 
both 4 °C and 37 °C confirmed that STR-KV/siRNA complexes were internalized through an 
energy-independent mechanism, most likely involving direct translocation. Utilizing physical 
and chemical endocytic inhibitors, i.e. Chlorpromazine, EIPA, MBCD, Filipin and Nystatin, 
was further approved this point. The confocal images were revealed that our complexes were 
uptake within 2 hours through a non-endocytic pathway on CHO-K1, A549 and HeLa cells. 
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7.2 Recommendations 
Recommended future work to develop peptide-based nanocarriers for efficient and safe 
siRNA delivery can be divided into following major parts: 
Addition of targeting ligands into peptide sequences to further improve the in vivo 
silencing efficiency 
Further modification could be applied to its sequence with addition of cell targeting 
ligands. Moreover, a conjugation with targeting ligands is the most commonly adopted 
methods to reduce systemic toxicity while improving therapeutic efficiency. Such 
modifications can be done by one of the following methods: 1) the targeting moiety is 
attached to one end of the original peptide chain if it is relatively short; 2) the targeting moiety 
is incorporated into the peptide assemblies by being attached onto the complex surface after 
the complexation. The commonly adopted targeting ligands involved antibodies, aptamers, 
small molecules, chemical modified polymers, short peptides, fatty acids, and others. Possible 
targeting moieties include the followings, depending on the desired targeting sites: 1) 
Transferrin. The conjugated nanoparticles might accumulate in targeting site 20 min after 
intravenous injection. 2) Human epidermal growth factor receptor-2 (Her2) antibody. The 
conjugated siRNA delivery systems resulted an inhibited breast tumor cell proliferation. 3) 
Tumor homing peptides was another useful targeting strategy in developing siRNA delivery 
system, e.g., Arg-Gly-Asp (RGD) peptide can effectively employed as targeting ligands. 
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    Evaluate therapeutic effect of peptide/siRNA complexes through intravenous injection 
in vivo: 
 Preliminary in vivo results showed in Chapter 4 that intratumoral injection of Bcl-2 
siRNA delivered by STR-HK significantly reduced the tumor proliferation rate in a xenograft 
NSCLC model with nude mice. To further investigate the possibility of systemic delivery, 
the complexes of Bcl-2 siRNA with promising peptides with high transfection efficiency and 
low toxicity in vitro can be applied intravenous injections, i.e., STR-HK and STR-KV. The 
potential animal model could be established as the same one used for intratumoral injection 
in Chapter 4, i.e., subcutaneous inoculation of 5×106 NSCLC A549 cells at the right armpit 
of six-week-old BALB/c nude mice. Tumor growth and treatments will be monitored and 
performed on alternative days. After injection, the circulating complexes in bloodstream will 
be accumulating in tumor either through EPR effects, or through conjugating with a targeting 
moiety. The mice will be sacrificed after the treatment periods. Several examinations will be 
performed to evaluate the knockdown efficiency of peptide/siRNA complexes: 1) Tumor 
tissue will be studied through microscopy for vascularization and angiogenesis; 2) The 
knockdown efficiency at protein level will be evaluated by western blotting; 3) The non-
evasive imaging of biodistribution and pharmacokinetics of complexes will be studied with 
fluorescently-labeled siRNAs with fluorescent optical microscopy. 
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